

CURRICULUM VITAE

NAME	Konstantinos Karmiris
DATE AND PLACE OF BIRTH	June 22nd, 1971, Athens, Greece
NATIONALITY	Greek
FAMILY STATUS	Married with one daughter
BUSINESS ADDRESS	Department of Gastroenterology Venizeleion General Hospital L. Knossou, PO BOX 44, Heraklion, Greece Tel. +30 2810368483 Fax +30 2810368018
HOME ADDRESS	Praisou 10, P.O.BOX 20, 71500, Heraklion, Greece Tel: +30 2810311982 Mobile: +30 6944143789
E-MAIL ADDRESS	kkarmiris@gmail.com

1. EDUCATION

1983 – 1989 High school Lyceé Leonin, Athens, Greece
1990 – 1997 University of Crete, Medical School, Greece, MD Degree 4/1997
10/2006 Diploma of specialist on Gastroenterology
04/2007 Permission to practice Gastroenterology in Belgium
11/2009 PhD in Medical Sciences
12/2010 Fellow of the European Board of Gastroenterology and Hepatology
03/2016 ICH Good Clinical Practice

2. LANGUAGES

Greek, English, French, Italian (basic), Dutch (basic)

3. ADDITIONAL KNOWLEDGE

A. COMPUTERS

Internet, Office, SPSS, Adobe, Reference manager

B. LABORATORY TECHNIQUES

1. ELISA
2. PCR
3. RNA & DNA extraction

4. PROFESSIONAL EXPERIENCE - APPOINTMENTS - DEGREES

05/1997 – 12/1998 Military services in the Air Force for 21 months (as a general practitioner)
02/1999 – 05/2002 Department of Internal Medicine (resident), Venizelion General Hospital, Heraklion

08/2002 – 08/2006	Department of Gastroenterology (resident), University Hospital, Heraklion
06/2007 – 06/2008	Endoscopy Unit (specialist), University Hospital Leuven
08/2008 – 03/2023	Venizeleio General Hospital (consultant), Heraklion
03/2023 – 12/2024	Venizeleio General Hospital (senior consultant), Heraklion

5. ENDOSCOPIC ACTIVITY (2007-12/2024)

1. Upper GI endoscopies: 6000 (including balloon or bougies dilatations, hemostatic procedures, banding, EMR)
2. Lower GI endoscopies: 9500 (including balloon dilatations, hemostatic procedures, EMR, eFTR, clipping)
3. Percutaneous endoscopic gastrostomies: 100

6. RESEARCH ACTIVITY

- 1996: Participation in research activities of the Laboratory of Pharmacology, University of Crete
- 1997 – 2000: Relationship of H. pylori with macrophages and MMPs, Laboratory of Gastroenterology, University of Crete
- 2002 – 2006: IBD study group, Department of Gastroenterology, University Hospital, Heraklion
- 2004 – 2009: The role of white adipose tissue and adipokines in inflammatory bowel diseases (PhD thesis)
- 2/2007 – 6/2008: Research on immunogenicity and on fistula closure effect of anti-TNF α agents in IBD patients, Department of Gastroenterology (IBD-Unit), University Hospitals Leuven, Belgium
- 8/2008 – 12/2024: Organisation of clinical studies as a staff member of the GI department of Venizeleion General Hospital

7. PARTICIPATION IN INTERNATIONAL COURSES

- 2004: 2nd ECCO course on IBD for residents & junior gastroenterologists, Dubrovnik, CRO
- 2005: IBD clinical observation program hosted by Professor Paul Rutgeerts, Leuven, BEL
- 2006: 4th ECCO course on IBD for residents & junior gastroenterologists, Amsterdam, NED
- 2007: IBD clinical observation program hosted by Professor Paul Rutgeerts, Leuven, BEL
- 2008: 1st YECCO workshop on presentation skills, Lyon, FRA
- 2017: Master class series of courses on clinical trials (50 hours), Heraklion, GRE
(under the auspices of Cambridge University Hospitals)

8. PARTICIPATION IN INTERNATIONAL SCIENTIFIC WORKING GROUPS

- 2009:** 1st ECCO Pathogenesis Workshop on “anti-TNF α loss of response”
- 2010:** 4th annual exchange on the advances in IBD (IBD Ahead 2010) bibliography group, Abbott Laboratories
- 2011:** 5th annual exchange on the advances in IBD (IBD Ahead 2011) bibliography group & faculty, Abbott Laboratories
- 2012:** 1st ECCO EpiCom workshop, 7th Congress of ECCO
- 2015-2016:** ECCO guidelines update on Ulcerative Colitis
- 2016-2022:** IBD cancer & serious infections in Europe: iCare study group (national representative)

2017-2020:	ECCO CONFER Steering Committee member
2019-2021:	ECCO guidelines update on Ulcerative Colitis treatment (GRADE methodology)
2019-2021:	ECCO guidelines update on prevention and management of infections
2020-2022:	ECCO guidelines on malignancies
2020-2025:	ECCO Educational Committee member (2020-2023) & chair (2023-2025)
2021-2023:	ECCO guidelines on extra-intestinal manifestations & anemia
2022-2024:	ECCO guidelines update on Crohn's Disease treatment (GRADE methodology)
2024-2026:	Multisociety (incl. ECCO) guidelines update on diagnostics & monitoring in IBD
2023-	spECTRUM (IntErnational Consortium of Therapeutic dRUg Monitoring) member
2023-	PSC-IBD Research Group member (in collaboration with ERN R-LIVER)
2024-	ECCO E-Quality Taskforce member
2025	20th Congress of ECCO, Berlin 2025 (Organizing Committee, member)
2025-2028:	ECCO Clinical Committee member

9. PARTICIPATION IN PHARMACEUTICAL CLINICAL TRIALS

1. A 6-week randomised, double-blind, double-dummy placebo-controlled, multicenter study to assess the effect of tegaserod 2mg t.i.d. and 6mg t.i.d., on dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy, Novartis, Protocol No CHTF919G2203 (phase III, terminated, sub-investigator).
2. Double-blind, double-dummy, randomised, multicenter study to compare the efficacy and safety of oral budesonide (9mg) and oral mesalazine (4.5gr) in moderately active Crohn's disease patients, Falk Pharma, Protocol BUC-52/CDA (mc320) (phase III, terminated, sub-investigator).
3. A long-term non-interventional registry to assess safety and effectiveness of Humira (adalimumab) in subjects with moderately to severely active Crohn's disease (CD), PYRAMID (P06-134), Abbvie (phase IV, terminated, sub-investigator).
4. Observational study on disease severity, evaluation tools and the long term impact of each treatment strategy in the daily clinical practice in patients with moderate to severe active Crohn's disease, P064840, MSD (phase IV, terminated, sub-investigator).
5. A long-term non-interventional registry to assess safety and effectiveness of Humira (adalimumab) in patients with moderately to severely active ulcerative colitis (UC), LEGACY (P11-282), Abbvie (phase IV, ongoing, sub-investigator).
6. A multicenter, non-interventional, observational study to assess the effect of Simponi (Golimumab) on quality of LIFE, healthcare resource utilization and work productivity among patients with ulcerative colitis in real world clinical setting in Greece, GO-LIFE (MK 8259-033), MSD (phase IV, terminated, sub-investigator).
7. Understanding the impact of ulcerative colitis and its associated disease burden on patients, ICONIC (P10641), Abbvie (phase IV, terminated, sub-investigator).
8. Post-marketing observational cohort study of patients with inflammatory bowel disease (IBD) treated with Inflectra (infliximab) in usual clinical practice, CONNECT-IBD (ZOB INF 1402), Hospira-Enorasis (phase IV, terminated, principal investigator).

10. EDITORIAL BOARD MEMBER IN PEER-REVIEWED JOURNALS

1. Journal of Crohn's and Colitis (**editorial board member**)
2. Annals of Gastroenterology (**Lower GI section editor**)
3. Frontiers in Gastroenterology, section: Therapy in Gastroenterology (**associate editor**)

11. REVIEWER IN PEER-REVIEWED JOURNALS, CONGRESSES & SCIENTIFIC PROJECTS

1. Alimentary Pharmacology and Therapeutics
2. Annals of Gastroenterology
3. BMC Gastroenterology
4. Clinical Gastroenterology & Hepatology
5. Digestive Liver Disease
6. European Journal of Gastroenterology & Hepatology
7. Frontiers in Gastroenterology
8. Inflammatory Bowel Diseases
9. Journal of Crohn's & Colitis
10. PLoS One
11. UEG Journal
12. ECCO Congress submitted abstracts
13. ECCO applications for fellowships/grants

12. SOCIETIES (MEMBERSHIP)

1. European Crohn's and Colitis Organisation (ECCO)
2. Hellenic Society of Gastroenterology
3. Hellenic Group for the Study of IBD (EOMIFNE) – **General Secretary**

13. GRANT ALLOCATIONS - HONORS - AWARDS

1. Twelve-month fellowship (2007) from the Hellenic Society of Gastroenterology and twelve-month fellowship (2008) from ECCO for a 2-years postgraduate program in the IBD field at the Department of Gastroenterology University Hospital, Leuven, Belgium
2. Best poster award in the 26th Hellenic Congress of Gastroenterology, Athens 2006
3. Best poster award in the 28th Hellenic Congress of Gastroenterology, Athens 2008
4. Best poster award in the 29th Hellenic Congress of Gastroenterology, Chalkidiki 2009
5. 2nd best oral presentation in the 33th Hellenic Congress of Gastroenterology, Thessaloniki 2013
6. 2nd best oral presentation in the 37th Hellenic Congress of Gastroenterology, Thessaloniki 2017
7. Best oral presentation in the 18th IBD Congress, Porto Heli 2019
8. 3rd best oral presentation in the 20th IBD Congress, Corfu 2022
9. Journal Crohn's and Colitis top reviewer for 2023

14. PUBLICATIONS – PRESENTATIONS – LECTURES – CONGRESS PARTICIPATION

Published full papers (peer-reviewed) (14 ^A)*	102
Accepted full papers (peer-reviewed) (14 ^B)*	-
Submitted full papers (peer-reviewed) (14 ^C)*	-
- Publications during the last 5 years	43
- Sum of journals' impact factor	559.1
- Mean journal impact factor	6
- 1 st author	12/93 (12,9%)
- 2 nd author	13/93 (14%)
- last author	8/93 (8,6%)
- 1 st , 2 nd & last author	33/93 (35,5%)
Published abstracts (peer-reviewed) (14 ^D)*	119
Oral presentations / Posters in international meetings (14 ^E)*	123
Publications in Greek journals (in English) (14 ^F)*	2
Oral presentations / Posters in major Greek congresses (14 ^G)*	107
Chapters in scientific books (14 ^H)*	2
Lectures in international congresses (14 ^I)*	17
Lectures in major Greek congresses (14 ^J)*	96
Participation in major international congresses (14 ^K)*	123
ECCO Congress educational / scientific program chair	2
ECCO Congress poster chair	4
Citations / H index registered in certified scientific platforms	
- Citations / H index (Scopus)	4321 / 31
- Citations / H index (Google Scholar)	6098 / 34
- i10 index (Google Scholar)	54

*below you can find a detailed analysis of all activities of every section in the table

14^A PUBLISHED FULL PAPERS

1. Koutroubakis IE, Malliaraki N, Dimoulis PD, **Karmiris K**, Castanas E, Kouroumalis EA. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. *Dig Dis Sci* 2004;49:1433-1437
2. Zacharioudakis G, Chrysos E, Athanasakis E, Tsiaoussis J, **Karmoiris K**, Xynos E. Is there any mediterranean diet not affecting bilitec assessment of bile reflux? *Digestion* 2004;70:84-92
3. Koutroubakis IE, Xidakis C, **Karmiris K**, Sfiridaki A, Kandidaki E, Kouroumalis EA. Serum angiogenin in inflammatory bowel disease. *Dig Dis Sci* 2004;49:1758-1762
4. **Karmiris K**, Koutroubakis IE, Kouroumalis EA. The emerging role of adipocytokines as inflammatory mediators in inflammatory bowel disease. *Inflamm Bowel Dis* 2005;11:847-855 [Review]
5. Koutroubakis IE, Drygiannakis D, **Karmiris K**, Drygiannakis I, Makreas S, Kouroumalis EA. Pancreatic autoantibodies in Greek patients with inflammatory bowel disease. *Dig Dis Sci* 2005;50:2330-2334
6. Koutroubakis IE, Xidakis C, **Karmiris K**, Sfiridaki A, Kandidaki E, Kouroumalis EA. Potential role of soluble angiopoietin-2 and tie-2 in patients with inflammatory bowel disease. *Eur J Clin Invest* 2006;36:127-132
7. **Karmiris K**, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin and ghrelin in inflammatory bowel disease. *Inflamm Bowel Dis* 2006;12:100-105
8. Koutroubakis IE, **Karmiris K**, Makreas S, Xidakis C, Niniraki M, Kouroumalis EA. Effectiveness of darbepoetin alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study. *Eur J Gastroenterol Hepatol* 2006;18:421-425

9. Koutroubakis IE, **Karmiris K**, Kouroumalis EA. Treatment of anaemia in inflammatory bowel disease. *Aliment Pharmacol Ther* 2006;23:1273-1274 [Letter]
10. Koutroubakis IE, Tsiolakidou G, **Karmiris K**, Kouroumalis EA. Role of angiogenesis in inflammatory bowel disease. *Inflamm Bowel Dis* 2006;12:515-523 [Review]
11. Koutroubakis IE, **Karmiris K**, Bourikas L, Drygiannakis D, Drygiannakis I, Kouroumalis EA. Antibodies against cyclic citrullinated peptide (CCP) in inflammatory bowel disease patients with or without arthritic manifestations. *Inflamm Bowel Dis* 2007;13:504-505 [Letter]
12. **Karmiris K**, Roussomoustakaki M, Tzardi M, Romanos J, Grammatikakis J, Papadakis M, Polychronaki M, Kouroumalis EA. Ileal malignant melanoma causing intussusception: report of a case. *Surg Today* 2007;37:506-509 [Case]
13. **Karmiris K**, Koutroubakis IE, Xidakis C, Polychronaki M, Kouroumalis EA. The effect of Infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2007;19:789-794
14. **Karmiris K**, Koutroubakis IE. Resistin: another rising biomarker in inflammatory bowel disease? *Eur J Gastroenterol Hepatol* 2007;19:1035-1037 [Editorial]
15. Stathaki MI, Koutroubakis IE, Koukouraki SI, **Karmiris KP**, Moschandreas JA, Kouroumalis EA, Karkavitsas NS. Active inflammatory bowel disease: head-to-head comparison between 99mTc-hexamethylpropylene amine oxime white blood cells and 99mTc(V)-dimercaptosuccinic acid scintigraphy. *Nucl Med Commun* 2008;29:27-32
16. **Karmiris K**, Koutroubakis IE, Kouroumalis EA. Leptin, adiponectin, resistin and ghrelin; implications for inflammatory bowel disease. *Mol Nutr Food Res* 2008;52:855-866 [Invited Review]
17. Koutroubakis IE, Oustamanolakis P, Malliaraki N, **Karmiris K**, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis EA. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2009;21:283-288
18. Theodoropoulou A, Konstantinidis K, Kteniadakis S, Tribonias G, Tzanoudakis G, Vardas E, **Karmiris K**, Psillakis K, Zois E, Tzortzakakis E, Paspatis GA. Intussusception following enteroscopy and ileo-colonoscopy in an adult with acquired immune deficiency syndrome. *Endoscopy* 2009;41 Suppl 2:E162-163 [Case]
19. **Karmiris K**, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. *Gastroenterology* 2009;137:1628-1640
20. Tribonias G, Theodoropoulou A, Konstantinidis K, Vardas E, **Karmiris K**, Chroniaris N, Chlouverakis G, Paspatis GA. Comparison of standard versus high-definition, wide-angle colonoscopy for polyp detection: A randomized controlled trial. *Colorectal Dis* 2010;12(10 online):e260-266
21. Paspatis GA, Chainaki I, Manolaraki MM, Vardas E, Theodoropoulou A, Tribonias G, Konstantinidis K, **Karmiris K**, Chlouverakis G. Efficacy of bispectral index monitoring as an adjunct to propofol deep sedation for ERCP: a randomized controlled trial. *Endoscopy* 2009;41:1046-1051
22. Tribonias G, Konstantinidis K, Theodoropoulou A, Vardas E, **Karmiris K**, Velegarakis M, Paspatis GA. Rectal perforation caused by colonoscopic retroflexion. *Gastrointest Endosc* 2010;71:662 [Case]
23. Koutroubakis IE, Drygiannakis D, Tsirogianni A, Oustamanolakis P, **Karmiris K**, Papamichael K, Mantzaris GJ, Kouroumalis EA. Antiglycan antibodies in Greek patients with inflammatory bowel disease. *Dig Dis Sci* 2011;56:845-852
24. van Asseldonk DP, Sanderson J, de Boer NK, Sparrow MP, Lémann M, Ansari A, Almer SH, Florin TH, Gearry RB, Mulder CJ, Mantzaris G, van Bodegraven AA, Barclay M, Roberts R, Irving P, Vergauwe P, **Karmiris K**, Opio V, San Román AL, van Soest E, Caccaro R, Marinaki T, Smith M, Metz A, Xavier R, Elliott T, Suzuki M, Bermejo F, van den Brande J, Caccaro R, Monti C. Thiopurine Task Force Interest Group. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease—proceedings of the first Thiopurine Task Force meeting. *Dig Liver Dis* 2011;43:270-276

25. **Karmiris K**, Bielen D, Vanbeckevoort D, Vermeire S, Coremans G, Rutgeerts P, Van Assche G. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease using magnetic resonance imaging. *Clin Gastroenterol Hepatol* 2011;9:130-136
26. Allez M, **Karmiris K**, Louis E, Van Assche G, Ben-Horin S, Klein A, Van der Woude J, Baert F, Eliakim R, Katsanos K, Brynskov J, Steinwurz F, Danese S, Vermeire S, Teillaud JL, Lemann M, Chowers Y. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. *J Crohns Colitis* 2010;4:355-366
27. Voudoukis E, Spiridakis KG, **Karmiris K**, Georgiou G, Kontopodis N, Konstantinidis K, Psilakis K, Miliadis O, Tribonias G, Paspatis GA. Intramural hematoma of the ascending colon leading to intraperitoneal hemorrhage: a possible post-polypectomy complication. *Ann Gastroenterol* 2012;25:265-267 [Case]
28. Ferrante M, **Karmiris K**, Newnham E, Siffledeen J, Zelinkova Z, van Assche G, Lakatos PL, Panés J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel JF, Panaccione R. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. *J Crohns Colitis* 2012;6:116-131
29. Tribonias G, **Karmiris K**, Konstantinidis K, Voudoukis E, Theodoropoulou A, Vardas E, Paspatis GA. Detection of CMV in pouch mucosa in a patient with acute pouchitis: The real enemy or an innocent bystander? *J Crohns Colitis* 2012;6:728-729 [Case]
30. Viazis N, Mantzaris G, **Karmiris K**, Polymeros D, Kouklakis G, Maris T, Karagiannis J, Karamanolis DG; Hellenic Foundation of Gastroenterology and Nutrition. Inflammatory bowel disease: Greek patients' perspective on quality of life, information on the disease, work productivity and family support. *Ann Gastroenterol* 2013;26:52-58
31. Papay P, Ignjatovic A, **Karmiris K**, Amarante H, Milheller P, Feagan B, D'Haens G, Marteau P, Reinisch W, Sturm A, Steinwurz F, Egan L, Panés J, Louis E, Colombel JF, Panaccione R. Optimizing monitoring in the management of Crohn's disease: a physician's perspective. *J Crohns Colitis* 2013;7:653-669
32. Voudoukis E, **Karmiris K**, Oustamanolakis P, Theodoropoulou A, Sfiridaki A, Paspatis GA, Koutroubakis IE. Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2013;10:1212-1216
33. Voudoukis E, **Karmiris K**, Koutroubakis IE. Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. *World J Gastroenterol* 2014;20:3180-3190 [Review]
34. **Karmiris K**, Bossuyt P, Sorrentino D, Moreels T, Scarcelli A, Legido J, Dotan I, Naismith GD, Jussila A, Preiss JC, Kruis W, Li AC, Bouguen G, Yanai H, Steinwurz F, Katsanos KH, Subramaniam K, Tarabar D, Zaganas IV, Ben-Horin S. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumor necrosis factor alpha agents. *J Crohns Colitis* 2015;9:382-389
35. Baert F, Kondragunta V, Lockton S, Vande Casteele N, Hauenstein S, Singh S, **Karmiris K**, Ferrante M, Gils A, Vermeire S. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. *Gut* 2016;65:1126-1131
36. Ternant D, **Karmiris K**, Vermeire S, Desvignes C, Azzopardi N, Bejan-Angoulvant T, van Assche G, Paintaud G. Pharmacokinetics of adalimumab in Crohn's disease. *Eur J Clin Pharmacol* 2015;71:1155-1157
37. Vavricka SR, Greuter T, Scharl M, Mantzaris G, Shitrit AB, Filip R, **Karmiris K**, Thoeringer CK, Boldys H, Wewer AV, Yanai H, Flores C, Schmidt C, Kariv R, Rogler G, Rahier JF; ECCO CONFER investigators. Cogan's syndrome in patients with inflammatory bowel disease - A case series. *J Crohns Colitis* 2015;9:886-890
38. **Karmiris K**, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, Oikonomou KA, Kostas A, Zampeli E, Papadopoulos V, Theodoropoulou A, Viazis N, Polymeros D, Michopoulos S, Bamias G, Kapsoritakis A, Karamanolis DG,

- Mantzaris GJ, Tzathas C, Koutroubakis IE. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. *J Crohns Colitis* 2016;10:429-436
39. Kopylov U, Katsanos KH, van der Woude CJ, **Karmiris K**, Hernandez V, Odes S, Papamichael K, Koutroubakis IE, Bojic D, Kaimakliotis I, Fiorino G, Papageorgiou N, Pineda JR, Strongili K, Sanroman L, Mantzaris GJ, Jojic N, Paspatis G, Christodoulou DK, Ben-Horin S, Tsianos EV. European experience with methotrexate treatment in Crohn's disease: a multicentre retrospective analysis. *Eur J Gastroenterol Hepatol* 2016;28:802-806
40. Voudoukis E, Vetsika EK, Giannakopoulou K, **Karmiris K**, Theodoropoulou A, Sfiridaki A, Georgoulis V, Paspatis GA, Koutroubakis IE. Distinct features of circulating microparticles and their relationship with disease activity in inflammatory bowel disease. *Ann Gastroenterol* 2016;29:180-187
41. Fragaki M, **Karmiris K**, Paspatis GA. Crohn's disease and Asperger syndrome: not just a coincidence? *Inflamm Bowel Dis* 2016;22:E19 [Case]
42. **Karmiris K**, Koutroubakis IE. Response to van den Heuvel et al. *J Crohn's Colitis* 2016;10:1374 [Letter]
43. Fiorino G, Cortes PN, Ellul P, Felice C, Karatzas P, Silva M, Lakatos PL, Bossa F, Ungar B, Sebastian S, Furfaro F, **Karmiris K**, Katsanos KH, Muscat M, Christodoulou DK, Maconi G, Kopylov U, Magro F, Mantzaris GJ, Armuzzi A, Boscà-Watts MM, Ben-Horin S, Bonovas S, Danese S. Discontinuation of infliximab in patients with ulcerative colitis is associated with increased risk of relapse: A multinational retrospective cohort study. *Clin Gastroenterol Hepatol* 2016;14:1426-1432
44. Harbord M, Eliakim R, Bettenworth D, **Karmiris K**, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; European Crohn's and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. *J Crohn's Colitis* 2017; doi:10.1093/ecco-jcc/jjx009
45. Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, **Karmiris K**, Cheon JH, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen MH, Har-Noy O, Bernstein CN. Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physician's practice. *World J Gastroenterol* 2017;23:2995-3002
46. Papastergiou V, Paraskeva KD, Fragaki M, Dimas I, Vardas E, Theodoropoulou A, Mathou N, Giannakopoulos A, **Karmiris K**, Mpitouli A, Apessou D, Giannikaki L, Karagiannis JA, Chlouverakis G, Paspatis GA. Cold versus hot endoscopic mucosal resection for nonpedunculated colorectal polyps sized 6-10mm: a randomized trial. *Endoscopy* 2017; doi:10.1055/s-0043-118594
47. Harbord M, Eliakim R, Bettenworth D, **Karmiris K**, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; European Crohn's and Colitis Organisation [ECCO]. Corrigendum: Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. *J Crohn's Colitis* 2017; 11:1512
48. Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Avni Biron I, Lopez-Serrano P, Casanova MJ, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Bar-Gil Shitrit A, Gutierrez A, Doherty GA, Fernandez-Salazar L, Martínez Cadilla J, Huguet JM, O'Toole A, Stasi E, Manceñido Marcos N, Villoria A, **Karmiris K**, Rahier JF, Rodriguez C, Diz-Lois Palomares M, Fiorino G, Benitez JM, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Ferrer Bradley I, Lopez-San Roman A, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, van Hoeve K, Torres P, Gravito-Soares M, Rudbeck-Resdal D, Bartolo O, Peixoto A, Martin G, Armuzzi A, Garre A, Donday MG, Martín de Carpi FJ, Gisbert JP. Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. *Am J Gastroenterol* 2018; 113:396-403

49. Fragaki M, **Karmiris K**. Editorial: monitoring vedolizumab trough serum concentration in inflammatory bowel disease- following the fate of anti-TNF-alpha agents? *Aliment Pharmacol Ther* 2018; 47:1323-1324
50. Sebastian S, Black C, Pugliese D, Armuzzi A, Sahn K, Elkady SM, Katsanos KH, Christodoulou DK, Selinger C, Maconi G, Fearnhead NS, Kopylov U, Davidov Y, Bosca-Watts MM, Ellul P, Muscat M, **Karmiris K**, Hart AL, Danese S, Ben-Horin S, Fiorino G. The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. *Aliment Pharmacol Ther* 2018; 48:941-950
51. Gatt K, Schembri J, Katsanos KH, Christodoulou D, **Karmiris K**, Kopylov U, Pontas C, Koutroubakis I, Foteinogiannopoulou K, Fabian A, Molnar T, Zammit D, Fragaki M, Balomenos D, Zingboim N, Ben Horin S, Mantzaris GJ, Ellul P. Inflammatory bowel disease and physical activity: a study on the impact of diagnosis on the level of exercise amongst patients with IBD. *J Crohns Colitis* 2019; 13:686-692
52. Fragaki M, Voudoukis E, Chliara E, Dimas I, Mpitouli A, Velegraki M, Vardas E, Theodoropoulou A, **Karmiris K**, Giannikaki L, Paspatis G. Complete endoscopic mucosal resection of malignant colonic sessile polyps and clinical outcome of 51 cases. *Ann Gastroenterol* 2019; 32:174-177
53. Viazis N, Pontas C, **Karmiris K**, Dimas I, Fragaki M, Paspatis G, Drygiannakis I, Koutroubakis IE, Moschovis D, Tzouvala M, Theocharis G, Tsolias C, Thomopoulos K, Zampeli E, Axiaris G, Michopoulos S, Belesiotou E, Banasa M, Maraki S, Kouskoumpekou F, Apostolopoulos G, Stamouli V, Prifti H, Mantzaris GJ. Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece. *Eur J Gastroenterol Hepatol* 2019; 31:773-776
54. Velegraki M, Flamourakis M, Kazamias G, Georgiou G, **Karmiris K**. Replacement resistant iron deficiency anemia in a patient with ulcerative colitis in remission: investigating beyond the obvious. *Inflamm Bowel Dis* 2019; 25: e123-e124
55. Vale Rodrigues R, Sladek M, Katsanos K, van der Woude CJ, Wei J, Vavricka SR, Teich N, Ellul P, Savarino E, Chaparro M, Beaton D, Oliveira AM, Fragaki M, Shitrit AB, Ramos L, **Karmiris K**; ECCO CONFER investigators. Diagnosis and outcome of esophageal Crohn's disease. *J Crohns Colitis* 2020; 14: 624-629
56. Mantaka A, Tsoukali E, Fragaki M, **Karmiris K**, Viazis N, Mantzaris GJ, Koutroubakis IE. The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2020; 32: 581-587.
57. **Karmiris K**. Racial differences in inflammatory bowel disease: a race with alternating winners? *Inflamm Bowel Dis* 2020; doi: 10.1093/ibd/izaa022
58. Mpitouli A, Kougkas N, Avgoustidis N, Ergazakis N, **Karmiris K**. Eosinophilic Fasciitis in a patient with Crohn's disease treated with infliximab. A rare coexistence or a drug-related manifestation? *Inflamm Bowel Dis* 2020; doi: 10.1093/ibd/izaa120
59. Mantaka A, Tsoukali E, Fragaki M, **Karmiris K**, Viazis N, Mantzaris GJ, Koutroubakis IE. Is there a role of renin-angiotensin system inhibitors in modulating inflammatory bowel disease outcome? *Eur J Gastroenterol Hepatol* 2020; 32: doi: 10.1097/MEG.0000000000001912.
60. Mantaka A, Tsoukali E, Fragaki M, **Karmiris K**, Viazis N, Mantzaris GJ, Koutroubakis IE. Reply to the letter to the Editor: 'The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease'. *Eur J Gastroenterol Hepatol* 2021; 32: 300-302.
61. Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, **Karmiris K**, Kopylov U, Kirshgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. *J Crohns Colitis* 2021; 15: 879-913.
62. Bamias G, Kokkotas G, Gizis M, Kapizioni C, **Karmiris K**, Koureta E, Kyriakos N, Leonidakis G, Makris K, Markopoulos P, Michalopoulos G, Michopoulos S, Papaconstantinou I, Polymeros D, Siakavellas SI, Triantafyllou K, Tsironi E, Tsoukali E, Tzouvala M, Viazis N, Xourafas V, Zacharopoulou E, Zampeli E, Zografos K, Papatheodoridis G, Mantzaris G. Predictors

of response to vedolizumab in patients with ulcerative colitis: results from the Greek VEDO-IBD cohort. *Dig Dis Sci* 2021; 1–11.

63. Paspatis GA, Fragaki M, Velegaki M, Mpitouli A, Nikolaou P, Tribonias G, Voudoukis E, **Karmiris K**, Theodoropoulou A, Vardas E. Paradigm shift in management of acute iatrogenic colonic perforations: 24-year retrospective comprehensive study. *Endosc Int Open* 2021; 9: E874-E880.

64. Raine T, Verstockt B, Kopylov U, **Karmiris K**, Goldberg R, Atreya R, Burisch J, Burke J, Ellul P, Hedin C, Holubar SD, Katsanos K, Lobaton T, Schmidt C, Cullen G. ECCO Topical Review: refractory inflammatory bowel disease. *J Crohns Colitis* 2021; 15: 1605-1620.

65. Foteinogiannopoulou K, **Karmiris K**, Axiaris G, Velegaki M, Gklavas A, Kapizioni C, Karageorgos C, Kateri C, Katsoula A, Kokkotis G, Koureta E, Lamouri C, Markopoulos P, Palatianou M, Pastras P, Fasoulas K, Giouleme O, Zampeli E, Theodoropoulou A, Theocharis G, Thomopoulos K, Karatzas P, Katsanos KH, Kapsoritakis A, Kourikou A, Mathou N, Manolakopoulos S, Michalopoulos G, Michopoulos S, Boubonaris A, Bamias G, Papadopoulos V, Papatheodoridis G, Papaconstantinou I, Pachiadakis I, Soufleris K, Tzouvala M, Triantos C, Tsironi E, Christodoulou DK, Koutroubakis IE; Hellenic group for the study of IBD. The burden and management of anemia in Greek patients with inflammatory bowel disease: a retrospective, multicenter, observational study. *BMC Gastroenterol* 2021; 21: 269.

66. Albshesh A, Taylor J, Savarino EV, Truyens M, Armuzzi A, Ribaldone DG, Shitrit AB, Fibelman M, Molander P, Liefferinckx C, Nancey S, Korani M, Rutka M, Barreiro-de Acosta M, Domislovic V, Suris G, Eriksson C, Alves C, Mpitouli A, di Jiang C, Tepeš K, Coletta M, Foteinogiannopoulou K, Gisbert JP, Amir-Barak H, Attauabi M, Seidelin J, Afif W, Marinelli C, Lobaton T, Pugliese D, Maharshak N, Cremer A, Limdi JK, Molnár T, Otero-Alvarin B, Krznaric Z, Magro F, **Karmiris K**, Raine T, Drobne D, Koutroubakis I, Chaparro M, Yanai H, Burisch J, Kopylov U. Effectiveness of third-class biologic treatment in Crohn's disease: a multi-center retrospective cohort study. *J Clin Med* 2021; 10: 2914.

67. Foteinogiannopoulou K, **Karmiris K**, Axiaris G, Velegaki M, Gklavas A, Kapizioni C, Karageorgos C, Kateri C, Katsoula A, Kokkotis G, Koureta E, Lamouri C, Markopoulos P, Palatianou M, Pastras P, Fasoulas K, Giouleme O, Zampeli E, Theodoropoulou A, Theocharis G, Thomopoulos K, Karatzas P, Katsanos KH, Kapsoritakis A, Kourikou A, Mathou N, Manolakopoulos S, Michalopoulos G, Michopoulos S, Boubonaris A, Bamias G, Papadopoulos V, Papatheodoridis G, Papaconstantinou I, Pachiadakis I, Soufleris K, Tzouvala M, Triantos C, Tsironi E, Christodoulou DK, Koutroubakis IE; Hellenic group for the study of IBD. Correction to: The burden and management of anemia in Greek patients with inflammatory bowel disease: a retrospective, multicenter, observational study. *BMC Gastroenterol* 2021; 21: 301.

68. Bamias G, Kokkotis G, Christidou A, Christodoulou DK, Delis V, Diamantopoulou G, Fessatou S, Gatopoulou A, Giouleme O, Kafritsa P, Kalantzis C, Kapsoritakis A, Karatzas P, **Karmiris K**, Katsanos K, Kevrekidou P, Kosmidis C, Mantaka A, Mathou N, Michalopoulos G, Michopoulos S, Papaconstantinou I, Papatheodoridis G, Polymeros D, Potamianos S, Pouloupoulos G, Protopapas A, Sklavaina M, Soufleris K, Theocharis G, Theodoropoulou A, Triantafyllidis JK, Triantafyllou K, Tsiolakidou G, Tsironi E, Tzouvala M, Viazis N, Xourgias V, Zacharopoulou E, Zampeli E, Mantzaris GJ. The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD. *Eur J Gastroenterol Hepatol* 2021. doi: 10.1097/MEG.0000000000002267.

69. Phillips F, Verstockt B, Sladek M, de Boer N, Katsanos K, **Karmiris K**, Albshesh A, Erikson C, Bergemalm D, Molnar T, Ellul P; ECCO CONFER investigators. Orofacial granulomatosis associated with Crohn's disease: a multi-centre case series. *J Crohns Colitis* 2021. doi: 10.1093/ecco-jcc/jjab158.

70. Phillips F, Verstockt B, Ribaldone DG, Guerra I, Teich N, Katsanos K, Filip R, Molnar T, **Karmiris K**. Diagnosis and outcome of extranodal primary intestinal lymphoma in inflammatory bowel disease: an ECCO CONFER case series. *J Crohns Colitis* 2021. doi: 10.1093/ecco-jcc/jjab164.

71. Spinelli A, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro-Sanchez M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, **Karmiris K**, Katsanos K, Kopylov U, Lakatos P, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Doherty G, Raine T, Panis Y. ECCO Guidelines on therapeutics in ulcerative colitis: surgical treatment. *J Crohns Colitis* 2021. doi: 10.1093/ecco-jcc/jjab177.
72. Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro-Sanchez M, Czuber-Dochan W, Eder P, Ellul P, Fidalgo C, Fiorino G, Gionchetti P, Gisbert JP, Gordon H, Hedin C, Holubar S, Iacucci M, **Karmiris K**, Katsanos K, Kopylov U, Lakatos P, Lytras T, Lyutakov I, Noor N, Pellino G, Piovani D, Savarino E, Selvaggi F, Verstockt B, Spinelli A, Panis Y, Doherty G. ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment. *J Crohns Colitis* 2021. doi: 10.1093/ecco-jcc/jjab178.
73. Goessens L, Colombel JF, Outtier A, Ferrante M, Sabino J, Judge C, Saeidi R, Rabbitt L, Armuzzi A, Domenech E, Michalopoulos G, Cremer A, García-Alonso FJ, Molnar T, **Karmiris K**, Gecse K, Van Oostrom J, Löwenberg M, Farkas K, Atreya R, Ribaldone DG, Selinger C, Hoentjen F, Bihin B, Sebastian S; European COMBIO study group, Rahier JF. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. *United European Gastroenterol J* 2021. doi: 10.1002/ueg2.12170.
74. Michalopoulos G, **Karmiris K**. When disease extent is not always a key parameter: Management of refractory ulcerative proctitis. *Curr Res Pharmacol Drug Discov* 2021;3:100071. doi: 10.1016/j.crphar.2021.100071. [Review]
75. Mantzaris GJ, Zeglinas C, Theodoropoulou A, Koutroubakis I, Orfanoudaki E, Katsanos K, Christodoulou D, Michalopoulos G, Tzouvala M, Moschovis D, Michopoulos S, Zampeli E, Soufleris K, Ilias A, Chatzievangelinou C, Kyriakakis A, Antachopoulou K, **Karmiris K**. The effect of early vs delayed initiation of adalimumab on remission rates in patients with Crohn's disease with poor prognostic factors: the MODIFY study. *Crohn's and Colitis* 360; 3. doi: 10.1093/crocol/otab064
76. Ellul P, Revés J, Abreu B, Chaparro M, Gisbert JP, Allocca M, Fiorino G, Barberio B, Zingone F, Pisani A, Cassar D, Michalopoulos G, Mantzaris G, Koutroubakis I, **Karmiris K**, Katsanos K, Ďuricova D, Burisch J, Madsen GR, Maaser C, Arebi N, Orfanoudaki E, Milivojevic V, Buisson A, Avedano L, Leone S, Torres J. Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in Inflammatory Bowel Disease patients: an international web-based survey. *J Crohns Colitis* 2022;16:1070-1078.
77. Orfanoudaki E, Zacharopoulou E, Kitsou V, **Karmiris K**, Theodoropoulou A, Mantzaris GJ, Tzouvala M, Michopoulos S, Zampeli E, Michalopoulos G, Karatzas P, Viazis N, Liatsos C, Bamias G, Koutroubakis IE, On Behalf Of The Hellenic Group For The Study Of IBD. Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease. *J Clin Med* 2022; 11: 641
78. Sciberras M, **Karmiris K**, Nascimento C, Tabone T, Nikolaou P, Theodoropoulou A, Mula A, Goren I, Yanai H, Amir H, Mantzaris GJ, Georgiadi T, Foteinogiannopoulou K, Koutroubakis I, Allocca M, Fiorino G, Furfaro F, Katsanos K, Fousekis F, Michalopoulos G, Camilleri L, Torres J, Ellul P. Mental health, work presenteeism and exercise in inflammatory bowel disease. *J Crohns Colitis*. 2022; 16: 1197-1201
79. Ben-Horin S, Har-Noy O, Katsanos KH, Roblin X, Chen M, Gao X, Schwartz D, Cheon JH, Cesarini M, Bojic D, Protic M, Theodoropoulou A, Abu-Kaf H, Engel T, Tang J, Veyrard P, Lin X, Mao R, Christodoulou D, **Karmiris K**, Knezevic-Ivanovski T; ComboMesa investigators. Corticosteroids and mesalamine versus corticosteroids for acute severe ulcerative colitis: a randomized controlled trial. *Clin Gastroenterol Hepatol* 2022; 20: 2868-2875.e1.
80. Zacharopoulou E, Orfanoudaki E, Tzouvala M, Tribonias G, Kokkotis G, Kitsou V, Almpani F, Christidou A, Viazis N, Mantzaris GJ, Tsafaridou M, **Karmiris K**, Theodoropoulou A, Papathanasiou E, Zampeli E, Michopoulos S, Tigkas S, Michalopoulos G, Laoudi E, Karatzas P, Mylonas I, Kyriakos N, Liatsos C, Kafetzi T, Theocharis G, Taka S, Panagiotopoulou K, Koutroubakis IE, Bamias G. Patients with inflammatory bowel diseases have impaired antibody production after anti-

- SARS-CoV-2 vaccination: results from a panhellenic registry. *Inflamm Bowel Dis* 2023; 29: 228-237. **81.** Stavrou EF, Chatzopoulou F, Antonatos C, Pappa P, Makridou E, Oikonomou K, Kapsoritakis A, Potamianos PS, **Karmiris K**, Tzathas C, Chatzidimitriou D, Vizirianakis IS, Vasilopoulos Y. Pharmacogenetic analysis of canonical versus noncanonical pathway of NF- κ B in Crohn's disease patients under anti-tumor necrosis factor- α treatment. *Pharmacogenet Genomics* 2022;32:235-241.
- 82.** Yanai H, Kagramanova A, Knyazev O, Sabino J, Haenen S, Mantzaris GJ, Mountaki K, Armuzzi A, Pugliese D, Furfaro F, Fiorino G, Drobne D, Kurent T, Yassin S, Maharshak N, Castiglione F, de Sire R, Nardone OM, Farkas K, Molnar T, Krznaric Z, Brinar M, Chashkova E, Livne Margolin M, Kopylov U, Bezzio C, Shitrit AB, Lukas M, Chaparro M, Truyens M, Nancey S, Lobaton T, Gisbert JP, Saibeni S, Bacsúr P, Bossuyt P, Schulberg J, Hoentjen F, Viganò C, Palermo A, Torres J, Revés J, **Karmiris K**, Velegraki M, Savarino E, Markopoulos P, Tsironi E, Ellul P, Suárez CC, Weissshof R, Ben-Hur D, Naftali T, Eriksson C, Koutroubakis IE, Foteinogiannopoulou K, Limdi JK, Liu E, Surís G, Calabrese E, Zorzi F, Filip R, Ribaldone DG, Snir Y, Goren I, Banai-Eran H, Broytman Y, Barak HA, Avni-Biron I, Ollech JE, Dotan I, Aharoni Golan M. Endoscopic postoperative recurrence in Crohn's disease after curative ileocecal resection with early prophylaxis by anti-TNF, vedolizumab or ustekinumab: a real-world multicenter european study. *J Crohns Colitis*. 2022; 16: 1882-1892.
- 83.** Amiot A, Rahier JF, Baert F, Nahon S, Hart A, Viazis N, Biancone L, Domenech E, Reenears C, Peyrin-Biroulet L, Beaugerie L, Burisch J; **I-CARE collaborator group**. The impact of COVID-19 on patients with IBD in a prospective European cohort study. *J Crohns Colitis* 2023; 17: 37-48
- 84.** Peyrin-Biroulet L, Rahier JF, Kirchesner J, Abitbol V, Shaji S, Armuzzi A, **Karmiris K**, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease. *Clin Gastroenterol Hepatol* 2022:S1542-3565(22)00916-8. doi: 10.1016/j.cgh.2022.09.018
- 85.** Ellul P, Schembri J, Vella Baldacchino A, Molnar T, Resal T, Alloca MA, Furfaro F, Dal Buono A, Theodoropoulou A, Fragaki M, Tsoukali E, Mantzaris GJ, Phillips F, Radford S, Moran G, Gonzalez HA, Shaji S, Fousekis F, Christodoulou D, Yanai H, Michalopoulos G, Tua J, Camilleri L, Papamichael K, **Karmiris K**, Katsanos K. Post-inflammatory polyps burden as a prognostic marker of disease-outcome in patients with inflammatory bowel disease. *J Crohns Colitis* 2022: jjac169. doi: 10.1093/ecco-jcc/jjac169
- 86.** ENiGMA CODE collaborators. Development of a core descriptor set for Crohn's anal fistula. *Colorectal Dis* 2022. doi: 10.1111/codi.16440.
- 87.** Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Sulais EA, Axelrad JE, Balendran K, Burisch J, de Ridder L, Derikx L, Ellul P, Greuter T, Iacucci M, Di Jiang C, Kapizioni C, **Karmiris K**, Kirchesner J, Laharie D, Lobatón Ortega T, Molnár T, Noor NM, Rao R, Saibeni S, Scharl M, Vavricka SR, Raine T. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. *J Crohns Colitis* 2022: jjac187. doi: 10.1093/ecco-jcc/jjac187
- 88.** Viazis N, Drygiannakis I, **Karmiris K**, Theodoropoulou A, Zampeli E, Tzouvala M, Bamias G, Liatsos C, Theocharis G, Vrakas S, Tsironi E, Mathou N, Mantaka A, Christidou A, Koustenis K, Veretanos C, Papathanasiou E, Zacharopoulou E, Tribonias G, Kitsou V, Kartsoli S, Theodoulou A, Michopoulos S, Thomopoulos K, Koutroubakis IE, Mantzaris GJ. The natural history of COVID-19 in vaccinated inflammatory bowel disease patients. *Dig Liver Dis* 2023: S1590-8658(22)00862-3. doi: 10.1016/j.dld.2022.12.012
- 89.** Nani P, Ladopoulou M, Papaioannou EH, Papagianni ED, Antonatos C, Xiropotamos P, Kapsoritakis A, Potamianos PS, **Karmiris K**, Tzathas C, Patsatsi A, Lazaridou E, Zafiriou E, Roussaki-Schulze A, Georgiou S, Grafanaki K, Georgakilas GK, Vasilopoulos Y. Pharmacogenetic analysis of the *MIR146A* rs2910164 and *MIR155* rs767649 polymorphisms and response to anti-TNF treatment in patients with Crohn's disease and psoriasis. *Genes (Basel)* 2023; 14: 445.

90. Katsoula A, Axiaris G, Mpitouli A, Palatianou M, Christidou A, Dimitriadis N, Nakos A, Pastras P, Kourkoulis P, Karatzas P, Moutzoukis M, Zlatinoudis C, Philippidis A, Kourikou A, Kokkotis G, Gklavas A, Machaira A, Mantaka A, Talimtzis P, Anagnostopoulou E, Koutroubakis IE, Papaconstantinou I, Bamias G, Manolakopoulos S, Mathou N, Paraskeva K, Protopappas A, Tsironi E, Katsanos KH, Christodoulou DK, Papatheodoridis G, Michalopoulos G, Theocharis G, Triantos C, Pachiadakis I, Soufleris K, Viazis N, Mantzaris GJ, Tribonias G, Tzouvala M, Theodoropoulou A, **Karmiris K**, Zampeli E, Michopoulos S, Haidich AB, Giouleme O. The inflammatory bowel disease-disk tool for assessing disability in inflammatory bowel disease patients: Validation of the Greek version. *J Clin Med* 2023; 12: 3023.
91. Gordon H, Burisch J, Ellul P, **Karmiris K**, Katsanos K, Allocca M, Bamias G, Barreiro-de Acosta M, Braithwaite T, Greuter T, Harwood C, Juillerat P, Lobaton T, Müller-Ladner U, Noor N, Pellino G, Savarino E, Schramm C, Soriano A, Stein JM, Uzzan M, van Rhee PF, Vavricka SR, Vecchi M, Zully S, Kucharzik T. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. *J Crohns Colitis* 2024; 18: 1-37.
92. Geldof J, Truyens M, Hanssens M, Van Gucht E, Holvoet T, Elorza A, Bouillon V, Barros S, Martins V, Argyriou K, Potamianos S, Diculescu M, Stroie T, Bossuyt P, Moens A, Theodoraki E, Koutroubakis IE, Pedro J, Fernandes S, Nikolaou P, **Karmiris K**, Baert FJ, Ferreira-Iglesias R, Peeters H, Claeys S, Casanova MJ, Eder P, Porter RJ, Arnott I, Karakan T, Mesonero F, Revés J, Van Dyck E, Jauregui-Amezaga A, Mañosa M, Rivière P, Marquez Mosquera L, Portela F, Pimentel R, Lobaton T. Prophylactic versus endoscopy-driven treatment of Crohn's postoperative recurrence: A retrospective, multicentric European study (PORCSE study). *J Crohns Colitis* 2024; 18: 1202-1214.
93. Allocca M, Catalano G, Savarino EV, Chaparro M, Levartovsky A, Michalopoulos G, Viazis N, Fousekis FS, Psistakis A, Noviello D, Neto do Nascimento C, Caron B, Kitsou V, Bamias G, Garcia MJ, Zacharopoulou E, Foteinogiannopoulou K, D'Amico F, Koutroubakis I, Ellul P, Tzouvala M, Peyrin-Biroulet L, Torres J, Caprioli F, **Karmiris K**, Theodoropoulou A, Katsanos KH, Christodoulou DK, Mantzaris GJ, Kopylov U, Gisbert JP, Danese S, Magro F, Fornari C, Fiorino G. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study. *United European Gastroenterol J* 2024; 12: 543-551.
94. Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, Warusavitarne J, Agrawal M, Allocca M, Atreya R, Battat R, Bettenworth D, Bislenghi G, Brown SR, Burisch J, Casanova MJ, Czuber-Dochan W, de Groof J, El-Hussuna A, Ellul P, Fidalgo C, Fiorino G, Gisbert J, Sabino JG, Hanzel J, Holubar S, Iacucci M, Iqbal N, Kapizioni C, **Karmiris K**, Kobayashi T, Kotze PG, Luglio G, Maaser C, Moran G, Noor N, Papamichail K, Peros G, Reenaers C, Sica G, Sigall-Boneh R, Vavricka SR, Yanai H, Myrelid P, Adamina M, Raine T. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. *J Crohns Colitis* 2024; 18: 1531-1555.
95. Adamina M, Gordon H, Raine T, Kopylov U, Verstockt B, Chaparro M, Buskens C, Warusavitarne J, Agrawal M, Allocca M, Atreya R, Battat R, Bettenworth D, Bislenghi G, Ross Brown S, Burisch J, Casanova MJ, Czuber-Dochan W, de Groof J, El-Hussuna A, Ellul P, Fidalgo C, Fiorino G, Gisbert J, Sabino JG, Hanzel J, Holubar S, Iacucci M, Iqbal N, Kapizioni C, **Karmiris K**, Kobayashi T, Kotze PG, Luglio G, Maaser C, Moran G, Noor N, Papamichail K, Peros G, Reenaers C, Sica G, Sigall-Boneh R, Vavricka SR, Yanai H, Myrelid P. ECCO guidelines on therapeutics in Crohn's disease: surgical treatment. *J Crohns Colitis*. 2024; 18: 1556-1582.
96. Paspatis G, Fragaki M, Arna DE, Velegraki M, Psistakis A, Nicolaou P, Psaroudakis I, Tribonias G, Voudoukis E, **Karmiris K**, Theodoropoulou A, Chlouverakis G, Vardas E. Long-term adenoma recurrence and development of colorectal cancer following endoscopic mucosal resection in large non-pedunculated colonic polyps ≥ 4 cm. *Dig Liver Dis* 2025; 57: 44-50.
97. Papathanasiou E, Kokkotis G, Axiaris G, Bellou G, Chalakatevaki K, Christidou A, Christodoulou DK, Foteinogiannopoulou K, Gatopoulou A, Giouleme O, Gkoumas K, Kalogirou M, Karatzas P, **Karmiris K**, Katsanos K, Kourikou A, Koutroubakis IE, Liatsos C, Mantzaris GJ, Mathou N, Michalopoulos G, Mantaka A, Nikolaou P, Oikonomou M, Papatheodoridis G, Polymeros D, Skouloudis E, Soufleris K, Stergiou E, Theodoulou A, Theodoropoulou A, Theocharis G,

Tsafaraki S, Tsiolakidou G, Tsironi E, Tzouvala M, Viazis N, Michopoulos S, Bamias G, Zampeli E. Pregnancy outcomes in Greek women with inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2025; 37: 154-160.

98. Markopoulos P*, **Karmiris K***, Dimas I, Voudoukis E, Siakavellas S, Axiaris G, Zacharopoulou E, Zampeli E, Tsironi E, Tzouvala M, Papatheodoridis G, Bamias G. Efficacy of vaccination and re-vaccination against hepatitis B virus using two different strategies in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2025; 31: 1317-1324.

99. Goren I*, Boldes OF*, Boldes T, Knyazev OV, Kagramanova AV, Limdi JK, Liu E, Holvoet T, Eder P, Bezzio C, Saibeni S, Venero M, Alimenti E, Chaparro M, Gisbert JP, Orfanoudaki E, Koutroubakis I, Pugliese D, Cuccia G, Suarez CC, Ribaldone DG, Veisman I, Sharif K, Aratari A, Papi C, Mylonas I, Mantzaris GJ, Truyens M, Nancey S, Castiglione F, Nardone OM, Calabrese G, **Karmiris K**, Velegraki M, Theodoropoulou A, Shitrit A, Lukas M, Vojtechova G, Ellul P, Bugeja L, Savarino EV, Fischler TS, Dotan I, Yanai H. Post-discharge outcomes of elderly patients hospitalized for inflammatory bowle disease flare complicated by Clostridioides difficile infection. *J Crohns Colitis* 2024: *jjæ161*, doi: 10.1093/ecco-jcc/jjæ161.

100. Honap S, Caron B, Ollech JE, Fischman M, Papanichael K, De Jong D, Gecse KB, Centritto A, Samaan MA, Irving PM, Sparrow MP, **Karmiris K**, Chateau T, Dotan I, Peyrin-Birulet L, on behalf of the International Consortium for Therapeutic Drug Monitoring (spECTRUM). Anti-tumor necrosis factor drug concentration is not associated with disease outcomes in pouchitis: a retrospective, international study. *Dig Dis Sci.* 2025; 70: 1320-1327.

101. Liatsos C, Tzouvala M, Michalopoulos G, Giouleme O, **Karmiris K**, Kozompoli D, Mousourakis K, Kyriakos N, Giakoumis M, Striki A, Karoubalis I, Bellou G, Zacharopoulou E, Katsoula A, Kalogirou M, Viazis N. Eficacy and safety of tofacitinib for the treatement of moderate-to-severe ulcerative colitis in biologic naïve patients to advanced therapies. *Eur J Gastroenterol Hepatol* 2025; 37: 427-432.

102. Viazis N, Karamanakis A, Mousourakis K, Christidou A, Fousekis F, Mpakogiannis K, Koukoudis A, Katsanos K, Christodoulou D, Cheila M, Tzouvala M, Zacharopoulou E, Palatianou M, Giouleme O, Katsoula A, Liatsos C, Kyriakos N, Zampeli E, Papathanasiou E, Theodoropoulou A, **Karmiris K**, Psaroudakis I, Tribonias G, Gazi S, Mole E, Dimitroulas T, Koutsianas C, Vassilopoulos D, Fragoulis GE, Michalakeas N, Papagoras C, Panagakis P, Papoutsaki M, Chasapi V, Stratigos A, Katsikas G. Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission. *Front Med (Lausanne)* 2025; 12: 1583401.

14^B ACCEPTED FULL PAPERS

14^C SUBMITTED FULL PAPERS

PEER-REVIEWED PUBLICATIONS STATISTICS

	Publication type	Publications (N)
1	Single center clinical studies	21
2	Multi-center clinical studies	33
3	ECCO guidelines	7
4	International workshops	6
5	Case series	5
6	Reviews	5
7	Editorials	3
8	Case reports	8
9	Letters to the Editor	5
		93

Journal	Publications (n)	1 st author	2 nd author	Last author	Journal's impact factor	Total impact factor
Gastroenterology	1	1			29,4	29,4
Gut	1				24,5	24,5
Clin Gastroenterol Hepatol	4	1		1	12,6	50,4
Am J Gastroenterol	1				10,2	10,2
Endoscopy	3				9,3	27,9
J Crohns Colitis	26	3	4	2	8	208
Gastrointest Endosc	1				7,7	7,7
Aliment Pharmacol Ther	3		1	1	7,6	22,8
United European Gastroenterology J	2				6	12
Eur J Clin Invest	1				5,5	5,5
Mol Nutr Food Res	1	1			5,2	5,2
Inflamm Bowel Dis	9	3	2	2	4,9	44,1
Dig Liver Dis	2				4,5	9
World J Gastroenterol	2		1		4,3	8,6
J Clin Med	3				3,9	11,7
Genes (Basel)	1				3,5	3,5
Colorectal Dis	2				3,4	6,8
Digestion	1				3,2	3,2
Dig Dis Sci	5				3,1	15,5
Curr Res Pharmacol Drug Discov	1			1	2,9	2,9
Eur J Clin Pharmacol	1		1		2,9	2,9
Pharmacogenet Genomics	1				2,6	2,6
Endosc Int Open	1				2,6	2,6
Surg Today	1	1			2,5	2,5
BMC Gastroenterology	2		2		2,4	4,8
Ann Gastroenterol	4				2,2	8,8
Eur J Gastroenterol Hepatol	11	2	2		2,1	23,1
Nucl Med Commun	1				1,5	1,5
Crohn's Colitis 360	1			1	1,4	1,4
	93	12	13	8		
Sum of impact factors						559,1
Mean impact factor						6

14^D PUBLISHED ABSTRACTS

1. Koutroubakis IE, Xidakis C, **Karmiris K**, Sfiridaki A, Kandidaki E, Kouroumalis EA. Serum angiogenin in inflammatory bowel disease. *Gut* 2004; 53 (Suppl. VI): A216
2. **Karmiris K**, Koutroubakis IE, Drygiannakis D, Makreas S, Drygiannakis I, Kiagiadaki C, Kouroumalis EA. Pancreatic autoantibodies are a specific marker for inflammatory bowel disease. *Gut* 2005; 54 (Suppl. VII): A169
3. Koutroubakis IE, **Karmiris K**, Makreas S, Xidakis, Kouroumalis EA. Effectiveness of darbepoetin alfa in patients with inflammatory bowel disease and refractory anaemia. *Gut* 2005; 54 (Suppl. VII): A182
4. Koutroubakis IE, Xidakis C, **Karmiris K**, Sfiridaki A, Kandidaki E, Kouroumalis EA. A potential role of soluble angiopoietin-2 and angiopoietin receptor Tie-2 in inflammatory bowel disease. *Gastroenterology* 2006; 130 (Suppl. 2): A199
5. Koutroubakis IE, **Karmiris K**, Makreas S, Xidakis C, Tsiolakidou G, Kouroumalis EA. Effectiveness of darbepoetin alfa, in combination with intravenous iron sucrose, in patients with inflammatory bowel disease and refractory anaemia. *Gastroenterology* 2006; 130 (Suppl. 2): A202
6. **Karmiris K**, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin and ghrelin in inflammatory bowel diseases. *Gastroenterology* 2006; 130 (Suppl. 2): A545

7. Stathaki M, Koutroubakis IE, Koukouraki S, **Karmiris K**, Kouroumalis EA, Karkavitsas N. Active Inflammatory Bowel Disease: head-to-head comparison between ^{99m}Tc-HMPAO-WBC and ^{99m}Tc (V) DMSA Scintigraphy. *Eur J Nucl Med Mol Imaging* 2006; 33(Suppl. 14): S359
8. Stathaki M, Koutroubakis IE, Koukouraki S, **Karmiris K**, Kouroumalis EA, Karkavitsas N. Active inflammatory bowel disease: head-to-head comparison between ^{99m}Tc-HMPAO-WBC and ^{99m}Tc (V) DMSA scintigraphy. *Gut* 2006; 55 (Suppl V): A120
9. **Karmiris K**, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Effect of Infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. *Gut* 2006; 55 (Suppl V): A139
10. Koutroubakis IE, **Karmiris K**, Xidakis C, Polychronaki M, Kouroumalis E. Effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. *J Crohns Colitis* 2007; 1 (Suppl. I): A13
11. **Karmiris K**, Koutroubakis IE, Xidakis C, Polychronaki M, Kouroumalis E. Effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. *Gastroenterology* 2007; 132 (Suppl. 2): A670
12. Stathaki M, Koutroubakis IE, Koukouraki S, **Karmiris K**, Kouroumalis EA, Karkavitsas N. Active inflammatory bowel disease: head-to-head comparison between ^{99m}Tc-HMPAO-WBC and ^{99m}Tc (V) DMSA scintigraphy. *Gastroenterology* 2007; 132 (Suppl. 2): A671
13. **Karmiris K**, Noman M, Schnitzler F, Fidder H, Koutroubakis IE, Kouroumalis EA, Vermeire S, Van Assche G, Rutgeerts P. Long-term efficacy and safety of adalimumab treatment in a single-center cohort of Crohn's disease patients who failed to infliximab treatment. *Acta Gastroenterol Belg* 2008; 71(Suppl. 1): D34
14. **Karmiris K**, Paintaud G, Degenne D, Ferrante M, Duveau A, Noman M, Van Assche G, Vermeire S, Rutgeerts P. Adalimumab trough serum levels and clinical response in a single-center cohort of inflammatory bowel disease patients: can trough serum levels serve as a predictor for future loss of response? *J Crohns Colitis* 2008; 2 (Suppl. I): A11
15. **Karmiris K**, Noman M, Schnitzler F, Fidder H, Koutroubakis IE, Kouroumalis EA, Vermeire S, Van Assche G, Rutgeerts P. Long-term efficacy and safety of adalimumab treatment in a single-center cohort of Crohn's disease patients who failed to infliximab treatment. *J Crohns Colitis* 2008; 2 (Suppl. I): A21
16. **Karmiris K**, Noman M, Paintaud G, Ferrante M, Duveau A, Degenne D, Van Assche G, Vermeire S, Rutgeerts P. A 3-week course of 80mg weekly administered adalimumab as a rescue therapy for patients with Crohn's disease who lost response to 40mg weekly: relationship with adalimumab trough serum levels. *J Crohns Colitis* 2008; 2 (Suppl. I): A27
17. **Karmiris K**, Paintaud G, Degenne D, Ferrante M, Duveau AC, Noman M, Van Assche G, Vermeire S, Rutgeerts P. Adalimumab trough serum levels and clinical response in a single-center cohort of inflammatory bowel disease patients: can trough serum levels serve as a predictor for future loss of response? *Gastroenterology* 2008; 134 (Suppl. 1): A68
18. **Karmiris K**, Noman M, Paintaud G, Ferrante M, Duveau AC, Degenne D, Van Assche G, Vermeire S, Rutgeerts P. A 3-week course of 80mg weekly administered adalimumab as a rescue therapy for patients with Crohn's disease who lost response to 40mg weekly: relationship with adalimumab trough serum levels. *Gastroenterology* 2008; 134 (Suppl. 1): A640
19. **Karmiris K**, Noman M, Schnitzler F, Fidder H, Koutroubakis IE, Kouroumalis EA, Vermeire S, Van Assche G, Rutgeerts P. Long-term efficacy and safety of adalimumab treatment in a single-center cohort of Crohn's disease patients who failed to infliximab treatment. *Gastroenterology* 2008; 134 (Suppl. 1): A658
20. **Karmiris K**, Vanbeckevoort D, Bielen D, Vermeire S, Rutgeerts P, Van Assche G. Baseline magnetic resonance imaging predicts surgery in perianal Crohn's disease patients treated with infliximab: results from a long-term follow-up study. *Gut* 2008; 57 (Suppl. II): A45
21. **Karmiris K**, Noman M, Vermeire S, Van Assche G, Rutgeerts P. Efficacy and safety of adalimumab in ulcerative colitis patients who failed infliximab treatment. *Gut* 2008; 57 (Suppl. II): A66

22. **Karmiris K**, Paintaud G, Degenne D, Duveau AC, Noman M, Van Assche G, Vermeire S, Rutgeerts P. Antibodies against adalimumab in Crohn's disease patients who failed infliximab treatment: correlation with clinical response and trough serum levels. *Gut* 2008; 57 (Suppl. II): A67
23. Oustamanolakis PI, Koutroubakis I, Malliaraki N, **Karmiris K**, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis E. Effects of TNF-alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. *Gut* 2008; 57 (Suppl. II): A68
24. Brinar M, De Hertogh G, **Karmiris K**, Cleynen I, Van Assche G, Geboes K, Rutgeerts P, Vermeire S. Allelic variations of autophagy-related 16-like 1 gene and immunity related guanosine phosphatase gene and granuloma formation in patients with Crohn's disease. *Gut* 2008; 57 (Suppl. II): A91
25. **Karmiris K**, Noman M, Vermeire S, Van Assche G, Rutgeerts P. Efficacy of adalimumab on extra-intestinal manifestations in patients with inflammatory bowel disease. *Gut* 2008; 57 (Suppl. II): A254
26. **Karmiris K**, Noman M, Vermeire S, Van Assche G, Rutgeerts P. Dose de-escalation in patients with inflammatory bowel disease treated long-term with adalimumab 40mg weekly. *Gut* 2008; 57 (Suppl. II): A255
27. Tribonias G, Konstantinidis K, Theodoropoulou A, Vardas E, **Karmiris K**, Chlouverakis G, Paspatis GA. Comparison of standard versus high definition colonoscopy for polyp detection: a randomised controlled trial. *Gut* 2009; 58 (Suppl. I): A121
28. Tribonias G, Konstantinidis K, Vardas E, Theodoropoulou A, Zois E, **Karmiris K**, Chlouverakis G, Paspatis GA. Comparison of standard versus high definition colonoscopy for polyp detection: a randomised controlled trial. *Gastrointest Endosc* 2009; 69: AB210
29. Tribonias G, Theodoropoulou A, Konstantinidis K, Vardas E, **Karmiris K**, Vidaki A, Chroniaris N, Chlouverakis G, Paspatis GA. Comparison of standard versus high definition colonoscopy for polyp detection: a randomised controlled trial. *Endoscopy* 2009; 41 (Suppl 1): A516
30. Oustamanolakis P, Koutroubakis IE, Drygiannakis D, **Karmiris K**, Karampasi A, Bourikas L, Kouroumalis EA. Antiglycan antibodies in Greek patients with inflammatory bowel diseases. *J Crohns Colitis* 2010; 4: S35
31. Trimponias G, Konstantinidis K, Theodoropoulou A, Vardas E, **Karmiris K**, Manolaraki M, Chlouverakis G, Paspatis GA. Deep sedation compared with moderate sedation in polyp detection during colonoscopy: a randomized controlled trial. *Gastrointest Endosc* 2010; 71: AB327
32. Trimponias G, Konstantinidis K, Theodoropoulou A, Vardas E, **Karmiris K**, Manolaraki M, Chlouverakis G, Paspatis GA. Deep sedation compared with moderate sedation in polyp detection during colonoscopy: a randomized controlled trial. *Endoscopy* 2010; 42 (Suppl I): A268
33. Ferrante M, **Karmiris K**, Compennolle G, Ballet V, Vermeire S, Noman M, Rutgeerts P, Gils A, Van Assche G. Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome. *Gut* 2011; 60 (Suppl. 3): A72
34. Ternant D, **Karmiris K**, Van Assche G, Vermeire S, Rutgeerts P, Paintaud G. Adalimumab pharmacokinetics and concentration-effect relationship in Crohn's disease. *Fund Clin Pharmacol* 2012; 26 (Suppl. 1): 119
35. Voudoukis E, **Karmiris K**, Oustamanolakis P, Charitakis A, Archontakis Z, Giannakopoulou K, Theodoropoulou A, Sfiridaki A, Paspatis G, Koutroubakis I. Thrombocytosis and iron deficiency in inflammatory bowel disease patients: a mutual relationship. *Gut* 2012; 61(Suppl. 3): A283
36. Voudoukis E, **Karmiris K**, Oustamanolakis P, Theodoropoulou A, Charitakis A, Archontakis Z, Giannakopoulou K, Sfiridaki A, Paspatis G, Koutroubakis I. Thrombocytosis and iron deficiency in inflammatory bowel disease patients: a mutual relationship. *J Crohns Colitis* 2013; 7(Suppl.1): S143
37. **Karmiris K**, Voudoukis E, Paspatis GA. Efficacy of vaccination against hepatitis A and B in inflammatory bowel disease patients: preliminary results. *J Crohns Colitis* 2013; 7(Suppl.1): S289-290

38. Voudoukis E, Tavernaraki A, Theodoropoulou A, **Karmiris K**, Vardas E, Giannakopoulou K, Paspatis GA. Split dose bowel preparation in detecting high risk patients for colon neoplasia: a prospective study (preliminary results). *UEG J* 2013; 1(Suppl.1): A176
39. **Karmiris K**, Avgerinos A, Tavernaraki A, Mantzaris GJ, Koukouratos T, Oikonomou K, Kostas A, Viazis N, Kapsoritakis A, Bamias G, Theodoropoulou A, Karamanolis DG, Koutroubakis IE. Prevalence and characteristics of extra-intestinal manifestations in a Greek population of inflammatory bowel disease patients followed-up in tertiary centers. *J Crohns Colitis* 2014; 7(Suppl.1): S320
40. **Karmiris K**, Avgerinos A, Tavernaraki A, Mantzaris GJ, Koukouratos T, Oikonomou K, Kostas A, Viazis N, Kapsoritakis A, Bamias G, Theodoropoulou A, Karamanolis DG, Koutroubakis IE. Prevalence and characteristics of dermatologic manifestations in a Greek population of inflammatory bowel disease patients followed-up in tertiary centers. *J Crohns Colitis* 2014; 7(Suppl.1): S320-321
41. **Karmiris K**, Voudoukis E, Choustoulaki M, Sfridaki A, Paspatis GA. Efficacy of vaccination against hepatitis A and B in inflammatory bowel disease patients. *J Crohns Colitis* 2014; 7(Suppl.1): S350
42. **Karmiris K**, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, Oikonomou K, Kostas A, Zampeli E, Papadopoulos V, Theodoropoulou A, Viazis N, Polymeros D, Michopoulos S, Bamias G, Kapsoritakis A, Karamanolis DG, Mantzaris G, Tzathas C, Koutroubakis IE. Hepatobiliary, pancreatic and renal manifestations in Greek inflammatory bowel disease patients. *UEG J* 2014; 2 (suppl. A132-605): A363
43. Kopylov U, Katsanos K, Van Der Woude CJ, **Karmiris K**, Hernandez V, Odes S, Papamichael K, Koutroubakis I, Bojic D, Kaimakliotis I, Papageorgiou N, Pineda JR, Strongili K, Sanroman L, Mantzaris G, Jojic N, Paspatis G, Christodoulou DK, Ben-Horin S, Tsianos EV. Safety and tolerability of methotrexate in inflammatory bowel disease – a multicenter european cohort study. *UEG J* 2015; 3 (suppl.1): A614
44. Kopylov U, Katsanos K, Van Der Woude CJ, **Karmiris K**, Hernandez V, Odes S, Papamichael K, Koutroubakis I, Bojic D, Kaimakliotis I, Papageorgiou N, Pineda JR, Strongili K, Sanroman L, Mantzaris G, Jojic N, Paspatis G, Christodoulou DK, Ben-Horin S, Tsianos EV. Methotrexate for maintenance of remission in Crohn's disease – a multicenter european cohort study. *UEG J* 2015; 3 (suppl.1): A614
45. Fiorino G, Ellul P, Muscat M, Karatzas P, Silva M, Peixoto A, Felice C, Bossa F, Lakatos PL, Sebastian S, Ungar B, Furfaro F, **Karmiris K**, Katsanos KH, Navarro Cortes P, Bosca Watts MM, Christodoulou DK, Maconi G, Kopylov U, Armuzzi A, Magro F, Mantzaris G, Ben-Horin S, Danese S. Infliximab discontinuation is associated with a higher risk for relapse in patients with ulcerative colitis in remission: a multinational collaborative retrospective study. *J Crohns Colitis* 2016; 10(Suppl.1): S47
46. Fiorino G, Ellul P, Muscat M, Karatzas P, Silva M, Peixoto A, Felice C, Bossa F, Lakatos PL, Sebastian S, Ungar B, Furfaro F, **Karmiris K**, Katsanos KH, Navarro Cortes P, Bosca Watts MM, Christodoulou DK, Maconi G, Kopylov U, Armuzzi A, Magro F, Mantzaris G, Ben-Horin S, Danese S. Infliximab discontinuation is associated with a higher risk for relapse in patients with ulcerative colitis in remission: a multinational collaborative retrospective study. *Gastroenterology* 2016; 150(Suppl.1): S6
47. Fiorino G, Navarro Cortes P, Ellul P, Felice C, Karatzas P, Silva M, Lakatos PL, Bossa F, Sebastian S, Ungar B, Furfaro F, **Karmiris K**, Katsanos KH, Muscat M, Christodoulou DK, Maconi G, Kopylov U, Magro F, Mantzaris G, Armuzzi A, Bosca Watts MM, Ben-Horin S, Bonovas S, Danese S. Discontinuation of infliximab in patients with ulcerative colitis is associated with increased risk of relapse: a multinational retrospective cohort study. *Gut* 2016; 65(Suppl.1): A88-A89
48. Fragkaki M, Bachlitzanaki M, **Karmiris K**, Theodoropoulou A, Vardas E, Paspatis G. Inflammatory bowel disease and colorectal cancer: interim analysis of a single center retrospective chart review. *UEG J* 2016; 4 (suppl.): A431

49. Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Avni Biron I, Lopez-Serrano P, Casanova M, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Bar-Gil Shitrit A, Gutierrez A, Doherty G, Fernandez-Salazar L, Cadilla Martinez J, Huguet J, O'Toole A, Stasi E, Mancenido Marcos N, Villoria A, **Karmiris K**, Rahier J, Rodriguez C, Diz-Lois Palomares M, Fiorino G, Benitej J, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Ferrer Bradley I, Lopez-San Roman A, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, Van Hoeve K, Torres P, Gravito-Soares E, Rudbeck-Thomsen D, Bartolo O, Peixoto A, Martin G, Perez J, Garre A, Donday MG, Martin de Capri J, Gisbert JP, Gastroenterology Units, on behalf of the TEDDY study group investigators. Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY study. *J Crohns Colitis* 2017; 11(Suppl.1): S34-35
50. Sebastian S, Black C, Nair MV, Drskova T, Hradsky O, Tzivnikos C, Sahnian K, Muhammed R, Devadason D, Parmar RS, Crook K, Akbar A, Thomson M, Pugliese D, Armuzzi A, Katsanos KH, Christodoulou DK, Selinger C, Maconi G, Fiorino G, Kopylov U, Bosca-Watts MM, **Karmiris K**, Ellul P, Ben-Horin S, Danese S, Hart AL. Differences in therapeutic approaches and outcomes in paediatric and adult onset Crohn's disease with perianal fistula: comparison of 2 multicenter fistula cohorts. *J Crohns Colitis* 2017; 11(Suppl.1): S183-184
51. Black C, Pugliese D, Sahnian K, Armuzzi A, Elkady SM, Hart AL, Katsanos KH, Christodoulou DK, Selinger C, Maconi G, Fiorino G, Davidov Y, Kopylov U, Ben-Horin S, Navarro P, Bosca-Watts MM, Muscat M, Ellul P, **Karmiris K**, Allgar V, Danese S, Fearnhead N, Sebastian S. Presentation and surgical interventions for Crohn's disease with perianal fistula in the biologics era: results from a multicentre study. *J Crohns Colitis* 2017; 11(Suppl.1): S199-200
52. Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, **Karmiris K**, Cheon JH, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen M, Har-Noy O, Bernstein CN. Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practice. *J Crohns Colitis* 2017; 11(Suppl.1): S250
53. Sebastian S, Black C, Pugliese D, Armuzzi A, Sahnian K, Elkady SM, Katsanos KH, Christodoulou DK, Selinger C, Maconi G, Fiorino G, Kopylov U, Davidov Y, Bosca-Watts MM, Ellul P, Muscat M, **Karmiris K**, Fearnhead NS, Allgar V, Hart AL, Ben-Horin S, Danese S. Multicenter cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula. *J Crohns Colitis* 2017; 11(Suppl.1): S330
54. Fragaki M, Bachlitzanaki M, **Karmiris K**, Theodoropoulou A, Vardas E, Paspatis G. Inflammatory bowel disease and colorectal cancer: analysis of a single center retrospective chart review. *J Crohns Colitis* 2017; 11(Suppl.1): S444
55. Shaji S, Black C, Pugliese D, Selinger C, Sahnian K, Hart A, Katsanos K, Christodoulou D, Maconi G, Fiorino G, Kopylov U, Davidov Y, Bosca-Watts MM, Muscat M, Ellul P, **Karmiris K**, Allgar V, Fearnhead N, Armuzzi A, Ben-Horin S, Danese S. Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula. *Gastroenterology* 2017; 152(Suppl.1): S778
56. Shaji S, Black C, Pugliese D, Armuzzi A, Sahnian K, Katsanos K, Christodoulou D, Selinger C, Maconi G, Fiorino G, Kopylov U, Davidov Y, Allgar V, Bosca-Watts MM, Ellul P, **Karmiris K**, Ben-Horin S, Hart A, Fearnhead N, Danese S. Presentation and surgical interventions for Crohn's disease with perianal fistula in the biologics era: results from a multicentre study. *Gastroenterology* 2017; 152(Suppl.1): S1282
57. Papastergiou V, Fragaki M, Dimas I, Vardas E, Theodoropoulou A, Mathou N, Giannakopoulos A, **Karmiris K**, Apessou D, Giannikaki L, Chlouverakis G, Paraskeva K, Paspatis G. Randomized comparison of injection-assisted cold snare polypectomy versus endoscopic mucosal resection for small (6-10mm) colorectal polyps. *Gastrointest Endosc* 2017; 85: AB358-359

58. Tzivinikos C, Nair MV, Ashton K, Drskova T, Sahnun K, Muhammed R, Devadason D, Hradsky O, Crook K, Palmer R, Akbar A, Thomson M, Hart A, Fiorino G, Black C, Pugliese D, Armuzzi A, Katsanos K, Christodoulou D, Maconi G, Selinger C, Kopylov U, Bosca-Watts M, **Karmiris K**, Ellul P, Ben-Horin S, Danese S, Sebastian S. Differences in therapeutic approaches and outcomes in paediatric and adult onset Crohn's disease with perianal fistula: comparison of 2 ECCO collaborative multicenter fistula cohorts. *Gut* 2017; 66(Suppl.2): OC-072
59. Black C, Pugliese D, Sahnun K, Hart A, Fiorino G, Armuzzi A, Katsanos K, Christodoulou D, Selinger C, Maconi G, Kopylov U, Bosca-Watts M, **Karmiris K**, Myers S, Davidov Y, Ellul P, Ben-Horin S, Danese S, Fearnhead N, Sebastian S. Presentation and surgical interventions for Crohn's disease with perianal fistula in the biologics era: results from a multicentre study. *Gut* 2017; 66(Suppl.2): PWE-033
60. Papastergiou V, Fragkaki M, Dimas I, Mpitouli A, Vardas E, Theodoropoulou A, Mathou N, Giannakopoulos A, **Karmiris K**, Apessou D, Giannikaki L, Chlouverakis G, Paraskeva K, Paspatis G. Cold snare polypectomy with submucosal pre-lift versus endoscopic mucosal resection for 6-10mm colorectal polyps: a randomized non-inferiority trial. *UEG J* 2017; 5 (suppl.): A221
61. Fragkaki M, Mpitouli A, Dimas I, Paspatis G, **Karmiris K**. Tuberculin skin test conversion rate in inflammatory bowel disease patients receiving anti-TNFalpha agents. *UEG J* 2017; 5 (suppl.): A303
62. Fragkaki M, Chliara E, Dimas I, Mpitouli A, Vardas E, Theodoropoulou A, **Karmiris K**, Voudoukis E, Giannikaki L, Paspatis G. Complete endoscopic mucosal resection of malignant colonic sessile polyps and clinical outcome of 51 cases. *UEG J* 2017; 5 (suppl.): A328
63. Fragkaki M, Chliara E, Dimas I, Mpitouli A, Vardas E, Theodoropoulou A, **Karmiris K**, Voudoukis E, Giannikaki L, Paspatis G. Complete endoscopic mucosal resection of malignant colonic sessile polyps and clinical outcome of 51 cases. *UEG J* 2017; 5 (suppl.): A328
64. Gatt K, Schembri J, Katsanos KH, Christodoulou DK, Balomenos D, **Karmiris K**, Pontas C, Kopylov U, Koutroubakis I, Foteinogiannopoulou K, Fabian A, Molnar T, Zammit D, Ellul P, Mantzaris GJ. Levels of engagement in physical activity and fatigue in IBD patients. *J Crohns Colitis* 2018; 12(Suppl.1): S250
65. Schembri J, Gatt K, Katsanos KH, Christodoulou DK, Balomenos D, **Karmiris K**, Pontas C, Kopylov U, Koutroubakis I, Foteinogiannopoulou K, Fabian A, Molnar T, Zammit D, Ellul P, Mantzaris GJ. A study on the impact of diagnosis on the level of exercise amongst patients with IBD. *J Crohns Colitis* 2018; 12(Suppl.1): S260-261
66. Fragaki M, Paspatis G, **Karmiris K**. Tuberculin skin test conversion rate in inflammatory bowel disease patients receiving anti-TNFα agents. *J Crohns Colitis* 2018; 12(Suppl.1): S375
67. Mantaka A, Tsoukali E, Fragaki M, **Karmiris K**, Viazis N, Mantzaris G, Koutroubakis I. Disease severity in patients with inflammatory bowel disease associated with cardiovascular diseases. *J Crohns Colitis* 2018; 12(Suppl.1): S521
68. Viazis N, Pontas C, Belesiotou E, **Karmiris K**, Dimas I, Fragaki M, Paspatis G, Banasa M, Drygiannakis I, Koutroubakis I, Maraki S, Moschovis D, Tzouvala M, Kouskoumpekou F, Theocharis G, Tsolias C, Thomopoulos K, Apostolopoulos G, Stamouli V, Zampeli E, Axiaris G, Michopoulos S, Prifti H, Mantzaris GJ. Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece. *J Crohns Colitis* 2018; 12(Suppl.1): S561
69. Fragaki M, Voudoukis E, Chliara E, Dimas I, Mpitouli A, Vardas E, Theodoropoulou A, **Karmiris K**, Giannikaki L, Paspatis G. Complete endoscopic mucosal resection of malignant colonic sessile polyps and clinical outcome of 51 cases. *Endoscopy* 2018; 50(04): S79
70. Fragaki M, Voudoukis E, Chliara E, Dimas I, Mpitouli A, Vardas E, Theodoropoulou A, **Karmiris K**, Velegraki M, Giannikaki L, Paspatis G. Complete endoscopic mucosal resection of malignant colonic sessile polyps and clinical outcome of 51 cases. *Gastrointest Endosc* 2018; 87: AB471

71. Mantaka A, Tsoukali E, Fragaki M, **Karmiris K**, Viazis N, Mantzaris G, Koutroubakis I. Disease severity in patients with inflammatory bowel disease associated with cardiovascular diseases. *UEG J* 2018; 6 (suppl. 1): A439
72. Rodrigues R, Sladek M, Katsanos K, Van der Woude CJ, Wei J, Teich N, Ellul P, Savarino E, Chaparro M, Beaton D, Oliveira AM, Fragaki M, Shitrit Bar-Gil A, Ramos L, **Karmiris K**. Oesophageal Crohn's disease: diagnosis and outcome of an ECCO-CONFER case series. *J Crohns Colitis* 2019; 13(Suppl. 1): S212-213
73. Fragaki M, Pasparaki E, Bibaki E, Kounalakis G, Ferdoutsis E, Paspatis G, Meletis G, **Karmiris K**. Pulmonary function tests in asymptomatic patients with inflammatory bowel disease: preliminary results of a single-center cohort study. *J Crohns Colitis* 2019; 13(Suppl. 1): S219-220
74. Lisle J, Myers S, Pugliese D, Raine T, de Vries AC, Katsanos K, Filip R, **Karmiris K**, Sebastian S. Drug induced liver injury (DILI) secondary to biologic therapy in IBD: ECCO-CONFER series. *J Crohns Colitis* 2019; 13(Suppl. 1): S403
75. Mantaka A, Tsoukali E, Fragaki M, **Karmiris K**, Viazis N, Mantzaris G, Koutroubakis I. Association between the use of antihypertensive agents and disease severity in patients with inflammatory bowel disease. *J Crohns Colitis* 2019; 13(Suppl. 1): S497
76. Dimas I, Voudoukis E, Paspatis G, **Karmiris K**. Efficacy of vaccination against hepatitis A in inflammatory bowel disease: a single-centre cohort study. *J Crohns Colitis* 2019; 13(Suppl. 1): S540-541
77. Dimas I, Voudoukis E, Paspatis G, **Karmiris K**. Post-vaccination kinetics of antibodies against hepatitis B surface antigen in inflammatory bowel disease patients: a single-center cohort study. *J Crohns Colitis* 2019; 13(Suppl. 1): S545
78. Mantaka A, Tsoukali E, Fragaki M, **Karmiris K**, Viazis N, Mantzaris GJ, Koutroubakis IE. Association between the use of antihypertensive agents and disease severity in patients with inflammatory bowel disease. *Gastroenterology* 2019; 156(Suppl. 1): S405
79. Mantzaris GJ, Theodoropoulou A, **Karmiris K**, Koutroubakis IE, Orfanoudaki E, Katsanos K, Xourgias V, Michalopoulos G, Tzouvala M, Moschovis D, Michopoulos S, Zampeli E, Soufleris K, Kafalis N, Ilias A, Stefanidis E, Chatzievangelinou C, Kyriakakis A, Zeglinas C. A retrospective study to examine the impact of Crohn's disease duration on adalimumab's effectiveness to achieve remission in patients bearing poor prognostic factors: the "MODIFY" study. *Gastroenterology* 2019; 156(Suppl. 1): S881
80. Fragaki M, Pasparaki E, Bibaki E, Kounalakis G, Theodoropoulou A, Ferdoutsis E, Paspatis G, Meletis G, **Karmiris K**. Pulmonary function tests in asymptomatic patients with inflammatory bowel disease: preliminary results of a single center cohort study. *UEG J* 2019; 7 (suppl. 1): A607
81. Phillips E, Verstockt B, Ribaldone D, Guerra I, Teich N, Katsanos K, Filip R, Molner T, **Karmiris K**. Extranodal primary intestinal lymphoma in inflammatory bowel disease: an ECCO CONFER multi-center case series. *J Crohns Colitis* 2020; 14(Suppl. 1): S305.
82. **Karmiris K**, Fotinogiannopoulou K, Velegriaki M, Koureta E, Axiaris G, Kateri C, Kokkotis G, Kapizioni C, Markopoulos P, Katsoula A, Gklavas A, Papaconstantinou I, Giouleme O, Tsironi E, Michalopoulos G, Bamias G, Papadopoulos V, Kapsoritakis A, Zampeli E, Michopoulos S, Karatzas P, Papatheodoridis G, Theodoropoulou A, Koutroubakis IE. Prevalence and management of anemia in Greek patients with inflammatory bowel disease: a multicentre real-life cohort study. *J Crohns Colitis* 2020; 14(Suppl. 1): S231-232.
83. Phillips E, Verstockt B, Sladek M, de Boer N, Katsanos K, **Karmiris K**, Albshesh A, Eriksson C, Bergemalm D, Molner T, Ellul P. Orofacial granulomatosis in Crohn's disease: an ECCO CONFER multi-center case series. *J Crohns Colitis* 2020; 14(Suppl. 1): S209-210.
84. Albshesh A, Taylor J, Savarino EV, Truysens M, Armuzzi A, Ribaldone DG, Shitrit A, Fibelman M, Molander P, Liefferinckx C, Nancy S, Korani M, Farkas K, Barreiro de Acosta M, Domislovic V, Suris G, Eriksson C, Alves C, Mpitouli A, Jiang CD, Tepeš K, Coletta M, Foteinogiannopoulou K, Afif W, Marinelli C, Lobaton Ortega T, Pugliese D, Maharshak N, Cremer A,

- Limdi JK, Molnár T, Otero-Alvarin B, Krznaric Z, Magro F, **Karmiris K**, Raine T, Drobne D, Koutroubakis I, Kopylov U. Effectiveness of third-class biologic treatment in Crohn's disease: a multi-center retrospective cohort study. *UEG J* 2020; 8(suppl.1): A429
85. Fragaki M, Velegraki M, Mpitouli A, Nikolaou P, Tribonias G, Voudoukis E, **Karmiris K**, Theodoropoulou A, Vardas E, Paspatis G. A paradigm shift in the management of acute iatrogenic colonic perforations: a 24-year retrospective comprehensive study. *Endoscopy* 2021; 53(S01): S189-S190
86. Bamias G, Kokkotis G, Christodoulou D, Delis V, Gatopoulou A, Giouleme O, Kalantzis C, Kapsoritakis A, Karatzas P, **Karmiris K**, Katsanos K, Kevrekidou P, Mathou N, Michalopoulos G, Michopoulos S, Papaconstantinou I, Polymeros D, Potamianos S, Pouloupoulos G, Protopappas A, Soufleris K, Theodoropoulou A, Triantafyllidis JK, Triantafyllou K, Tsiolakidou G, Tsironi E, Tzouvala M, Viazis N, Zacharopoulou E, Zampeli E, Papatheodoridis G, Mantzaris GJ. The natural history of COVID-19 in patients with IBD: A nationwide study by the Hellenic Society for the Study of IBD. *J Crohns Colitis* 2021; 15(Suppl.1): S571
87. Sciberras M, Nascimento C, Tabone T, **Karmiris K**, Nikolaou P, Theodoropoulou A, Mula A, Goren I, Yanai H, Amir H, Mantzaris G, Georgiadi T, Foteinogiannopoulou K, Koutroubakis I, Allocca M, Fiorino G, Furfaro F, Katsanos KH, Fousekis F, Michalopoulos G, Torres J, Ellul P. Effects of Covid-19 on employment in IBD patients. *J Crohns Colitis* 2021; 15(Suppl.1): S575
88. Sciberras M, Nascimento C, Tabone T, **Karmiris K**, Nikolaou P, Theodoropoulou A, Mula A, Goren I, Yanai H, Amir H, Mantzaris G, Georgiadi T, Foteinogiannopoulou K, Koutroubakis I, Allocca M, Fiorino G, Furfaro F, Katsanos KH, Fousekis F, Michalopoulos G, Torres J, Ellul P. Mental health, work presenteeism and exercise in IBD patients. *J Crohns Colitis* 2021; 15(Suppl.1): S577
90. Sciberras M, Nascimento C, Tabone T, **Karmiris K**, Nikolaou P, Theodoropoulou A, Mula A, Goren I, Yanai H, Amir H, Mantzaris GJ, Georgiadi T, Foteinogiannopoulou K, Koutroubakis I, Allocca M, Fiorino G, Furfaro F, Katsanos KH, Fousekis F, Michalopoulos G, Torres J, Ellul P. Effects of COVID-19 on employment in IBD patients. *UEG J* 2021; 9(suppl.1): A386
91. Sciberras M, Nascimento C, Tabone T, **Karmiris K**, Nikolaou P, Theodoropoulou A, Mula A, Goren I, Yanai H, Amir H, Mantzaris G, Georgiadi T, Foteinogiannopoulou K, Koutroubakis I, Allocca M, Fiorino G, Furfaro F, Katsanos KH, Fousekis F, Michalopoulos G, Torres J, Ellul P. Mental health, work presenteeism and exercise in IBD patients. *UEG J* 2021; 9(suppl.1): A409
92. Bamias G, Kokkotis G, Christidou A, Christodoulou DK, Delis V, Diamantopoulou G, Fessatou S, Gatopoulou A, Giouleme O, Kafritsa Y, Kalantzis C, Kapsoritakis AN, Karatzas P, **Karmiris K**, Katsanos KH, Kevrekidou P, Kosmidis C, Mantaka A, Mathou N, Michalopoulos G, Michopoulos S, Papaconstantinou I, Papatheodoridis G, Polymeros D, Potamianos S, Pouloupoulos G, Protopapas A, Sklavaina M, Soufleris K, Theocharis G, Theodoropoulou A, Thomopoulos K, Triantafyllidis J, Triantafyllou K, Tsiolakidou G, Tsironi E, Tzouvala M, Viazis N, Xourgias V, Zacharopoulou E, Zampeli E, Mantzaris GJ. The natural history of COVID-19 in patients with IBD: a nationwide study by the Hellenic Society for the Study of IBD. *UEG J* 2021; 9(suppl.1): A429
93. Mpitouli A, Nikolaou P, Velegraki M, Psistakis A, Fragaki M, Vardas E, Paspatis G, **Karmiris K**, Theodoropoulou A. Inflammatory bowel disease patients with a first degree relationship bear striking similarities: a retrospective single center observational study. *UEG J* 2021; 9(suppl.1): A434
94. Vella Baldacchino A, Ellul P, Schembri J, Tua J, Molnar T, Resal T, **Karmiris K**, Theodoropoulou A, Fragaki M, Mantzaris G, Tsoukali E, Allocca M, Furfaro F, Moran G, Phillips F, Varyani F, Katsanos K, Fousekis F, Christodoulou D, Sebastian S, Gonzalez HA, Yanai H, Snir Y, Lerner Z, Michalopoulos G. Heavy pseudopolyp burden in inflammatory bowel disease predicts more severe disease: a multicenter cohort study. *UEG J* 2021; 9(suppl.1): A443

95. Katsoula A, Axiares G, Michopoulos S, Zampeli E, Mpitolou A, Theodoropoulou A, **Karmiris K**, Palatianou M, Tzouvala M, Tribonias G, Christidou A, Mantzaris GJ, Viazis N, Dimitriadis N, Soufleris K, Pachiadakis I, Boubonaris A, Nakos A, Pastras P, Triantos C, Theocharis G, Kourkoulis P, Michalopoulos G, Karatzas P, Papatheodoridis G, Moutzoukis M, Christodoulou D, Katsanos K, Zlatinoudis C, Tsironi E, Philippidis A, Protopappas A, Paraskeva K, Mathou N, Manolakopoulos S, Kourikou A, Kokkoti S, Bamias G, Gklavas A, Papaconstantinou I, Machaira A, Koutroubakis I, Anagnostopoulou E, Mantaka A, Talimtzis P, Gioulema O. The inflammatory bowel disease – disk tool for assessing disability in inflammatory bowel disease patients: validation of the Greek version. *UEG J* 2021; 9(suppl.1): A447
96. Mpitolou A, Nikolaou P, Theodoropoulou A, **Karmiris K**. Association of endoscopic with histologic remission in patients with inflammatory bowel disease in clinical remission treated with anti-TNF α agents. *UEG J* 2021; 9(suppl.1): A452
97. Cheon JH, Ben-Horin S, Har-Noy O, Katsanos K, Roblin X, Cheon MH, Abu-Kaf H, Gao X, Cesarini M, Bojic D, Theodoropoulou A, **Karmiris K**, Knezevic-Ivanovski T, Christodoulou D, Lin X. Combination corticosteroids with 5-ASA versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: a multicenter randomized controlled trial. *Gut Liver* 2021; 15(suppl.1): A4 (PS01-04)
98. Ben-Horin S, Har-Noy O, Katsanos KH, Xavier R, Chen MH, Gao X, Schwartz D, Cheon JH, Cesarini M, Bojic D, Protic M, Theodoropoulou A, Abu-Kaf H, Engel T, Tang J, Veyrard P, Lin X, Mao R, Christodoulou D, **Karmiris K**, Knezevic-Ivanovski T. Corticosteroids and 5-ASA versus corticosteroids alone for acute severe ulcerative colitis: a randomized controlled trial. *Gastroenterology* 2022; 162(Suppl.): S14
99. Viazis N, Theodoropoulou A, Zampeli E, **Karmiris K**, Tzouvala M, Bamias G, Koutroubakis I, Liatsos C, Koustenis K, Veretanos C, Papathanasiou E, Zacharopoulou E, Tribonias G, Kitsou V, Drygiannakis I, Michopoulos S, Mantzaris G. The natural history of COVID-19 in vaccinated inflammatory bowel disease patients. *J Crohns Colitis* 2022; 16(Suppl.1): i283
100. Ben-Horin S, Har-Noy O, Katsanos KH, Xavier R, Chen MH, Gao X, Schwartz D, Cheon JH, Cesarini M, Bojic D, Protic M, Theodoropoulou A, Abu-Kaf H, Engel T, Tang J, Veyrard P, Lin X, Mao R, Christodoulou D, **Karmiris K**, Knezevic-Ivanovski T; ComboMesa. Combination corticosteroids with 5-aminosalicylic acid versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: a multi-center randomized controlled trial. *J Crohns Colitis* 2022; 16(Suppl.1): i337
101. Reves J, Abreu B, Chaparro M, Gisbert JP, Allocca M, Fiorino G, Barberio B, Zingone F, Pisani A, Cassar D, Michalopoulos G, Mantzaris G, Mountaki K, Koutroubakis I, **Karmiris K**, Katsanos K, Duricova D, Burisch J, Madsen GR, Maaser C, Naila A, Orfanoudaki E, Milivojevic V, Buisson A, Avedano L, Leone S, Torres J, Ellul P. Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in inflammatory bowel disease patients: an international web-based survey. *J Crohns Colitis* 2022; 16(Suppl.1): i558
102. Orfanoudaki E, Zacharopoulou E, Kitsou V, **Karmiris K**, Theodoropoulou A, Mantzaris GJ, Tzouvala M, Michopoulos S, Zampeli E, Michalopoulos G, Karatzas P, Viazis N, Liatsos C, Bamias G, Koutroubakis IE. Real world use and adverse events of SARS-CoV-2 vaccination in Greek patients with inflammatory bowel disease. *J Crohns Colitis* 2022; 16(Suppl.1): i576
103. Zacharopoulou E, Orfanoudaki E, Kitsou V, Tzouvala M, Tribonias G, Mantzaris GJ, Viazis N, Christidou A, Almpiani F, **Karmiris K**, Theodoropoulou A, Tsafaridou M, Michopoulos S, Zampeli E, Papathanasiou E, Michalopoulos G, Tigkas S, Karatzas P, Laoudi E, Liatsos C, Kyriakos N, Mylonas I, Theocharis G, Koutroubakis IE, Bamias G. Patients with inflammatory bowel diseases on anti-TNF treatment have impaired antibody production after anti-SARS-CoV-2 vaccination: results from a Panhellenic registry. *J Crohns Colitis* 2022; 16(Suppl.1): i581
104. Reves J, Abreu BS, Chaparro M, Gisbert JP, Allocca M, Fiorino G, Barberio B, Zingone F, Pisani A, Cassar D, Michalopoulos G, Mantzaris GJ, Mountaki A, Koutroubakis IE, **Karmiris K**, Katsanos K, Duricova D, Burisch JM, Madsen GR, Maaser C, Arebi N, Orfanoudaki E, Milivojevic V, Buisson A, Avedano L, Leone S, Torres J, Ellul P. Implementation and

short-term adverse events of anti-SARS-CoV-2 vaccines in inflammatory bowel disease patients: an international web-based survey. *Gastroenterology* 2022; 162 (Suppl.): S1006

105. Orfanoudaki E, Zacharopoulou E, Kitsou V, **Karmiris K**, Theodoropoulou A, Mantzaris GJ, Tzouvala M, Viazis N, Michopoulos S, Zampeli E, Michalopoulos G, Karatzas P, Liatsos C, Bamias G, Koutroubakis IE. Real world use and adverse events of SARS-CoV-2 vaccination in Greek patients with inflammatory bowel disease. *Gastroenterology* 2022; 162 (Suppl.): S1006-S1007

106. Zacharopoulou E, Orfanoudaki E, Kitsou V, Tzouvala M, Tribonias G, Mantzaris GJ, Viazis N, Christidou A, Georgiadi T, **Karmiris K**, Theodoropoulou A, Tsafaridou M, Michopoulos S, Zampeli E, Papathanasiou E, Michalopoulos G, Tigkas S, Karatzas P, Laoudi E, Liatsos C, Kyriakos N, Mylonas I, Theocharis GJ, Kafentzi T, Koutroubakis IE, Bamias G. Patients with inflammatory bowel diseases on anti-TNF treatment have impaired antibody production after anti-SARS-CoV-2 vaccination: results from a Panhellenic registry. *Gastroenterology* 2022; 162 (Suppl.): S1007

107. Allocca M, Catalano G, Savarino EV, Chaparro Sanchez M, Levartovsky A, Michalopoulos G, Viazis N, Fousekis FS, Psistakis A, Noviello D, Neto do Nascimento C, Caron B, Kitsou V, Bamias G, Garcia MJ, Zacharopoulou E, Foteinogiannopoulou K, D'Amico F, Koutroubakis I, Ellul P, Tzouvala M, Peyrin-Biroulet L, Torres J, Caprioli F, **Karmiris K**, Theodoropoulou A, Katsanos KH, Christodoulou DK, Mantzaris GJ, Kopylov U, Gisbert J, Danese S, Magro F, Fiorino G. Third-line therapy in refractory ulcerative colitis: a comparison between tofacitinib and ustekinumab. *UEG J* 2022; 10 (S8): A121

108. Viazis N, Drygiannakis I, **Karmiris K**, Theodoropoulou A, Zampeli E, Tzouvala M, Bamias G, Liatsos C, Theocharis G, Vrakas S, Tsironi E, Mathou N, Mantaka A, Christidou A, Koustenis KP, Veretanos C, Papathanasiou E, Zacharopoulou E, Tribonias G, Kitsou V, Kartsoli S, Theodoulou A, Michopoulos S, Thomopoulos K, Koutroubakis I, Mantzaris GJ. The natural history of COVID-19 in vaccinated inflammatory bowel disease patients. *UEG J* 2022; 10 (S8): A242

109. Viazis N, Christodoulou DK, Giouleme O, Theodoropoulou A, Bamias G, Zampeli E, Koutroubakis I, Tzouvala M, **Karmiris K**, Mousavere I, Katsanos KH, Katsaros M, Kitsou V, Axiaris G, Michopoulos S, Foteinogiannopoulou K, Zacharopoulou E, Tribonias G, Mountaki K, Mantzaris GJ. Tofacitinib for the treatment of moderate – severe ulcerative colitis: the Greek experience. *UEG J* 2022; 10 (S8): A728

110. Nicolaou P, Theodoropoulou A, Psistakis A, Arna D, Velegraki M, Fragkaki M, **Karmiris K**, Vardas E, Paspatis G. The use of video capsule endoscopy (vce) in patients with a new diagnosis of Crohn's disease: the experience of one center. *J Crohns Colitis* 2023; 17 (Suppl.1): i302

111. Foteinogiannopoulou K, Nicolaou P, Mala A, Theodoraki E, Orfanoudaki E, Theodoropoulou A, **Karmiris K**, Koutroubakis I. The prevalence and risk factors for malignancies in patients with inflammatory bowel disease in Crete: a case control study. *J Crohns Colitis* 2023; 17 (Suppl.1): i896

112. Nikolaou P, Fragaki M, Psistakis A, Arna D, Velegraki M, **Karmiris K**, Theodoropoulou A, Vardas E, Paspatis G. Inflammatory fibroid polyps (IFPs) of the stomach: a benign tumour with different clinical manifestations. A single center study. *Endoscopy* 2023; 55 (S02): S306.

113. Geldof J, Truyens M, Hanssens M, Van Gucht E, Swietek N, Holvoet T, Rodriguez-Lago I, Elorza A, Bouillon V, Cremer A, Martins V, Argyriou K, Diculescu M, Moens A, Bossuyt P, Theodoraki E, Koutroubakis I, Fernandes SR, Pedro J, **Karmiris K**, Baert F, Ferreira-Iglesias R, Peeters H, Claeys S, Casanova MJ, Eder P, Porter R, Arnott IDR, Karakan T, Mesonero Gismero F, Reves J, Torres J, Van Dyck E, Jauregui-Amezaga A, Manosa Ciria M, Riviere P, Marquez Mosquera L, Portela F, Pimentel R, Lobaton T, PORCSE Study Group. Prophylactic versus endoscopy-driven treatment of Crohn's postoperative recurrence: completed results of a retrospective, multicentric, European study (PORCSE study). *UEG J* 2023; 11 (S8): A71

114. Goren I, Fallek Boldes O, Boldes T, Knyazev OV, Kagramanova A, Limdi JK, Liu E, Holvoet T, Eder P, Bezzio C, Saibeni S, Vernerio M, Alimenti E, Chaparro M, Gisbert J, Orfanoudaki E, Koutroubakis I, Pugliese D, Cuccia G, Calvino Suarez C,

Ribaldone DG, Veisman I, Sharif K, Aratari A, Papi C, Mylonas I, Mantzaris GJ, Truysens M, Nancey S, Castiglione F, Nardone OM, Calabrese G, **Karmiris K**, Velegraki M, Theodoropoulou A, Shitrit A, Lukas M, Vojtechova G, Ellul P, Bugeja L, Savarino EV, Dotan I, Yanai H. Outcomes of elderly patients hospitalized for inflammatory bowel disease flare complicated by Clostridioides Difficile infection – The ENTRIT Study Group. *UEG J* 2023; 11 (S8): A107

115. Shani U, State M, Negreanu L, Mateescu BR, Davidoiu AM, Silva I, Magro F, Lees CW, Plevris N, Roblin X, Castellet Farrus S, Lama YG, Wang S, Abad C, Imperatore N, Lukas M, Vojtechova G, Regev O, Ben-Horin S, Nancey S, Savarino E, Stawczyk-Eder K, Eder P, Toskas A, Kamperidis N, Arebi N, Farkas B, Farkas K, Pipek B, Falt P, **Karmiris K**, Nicolaou P, Krznaric Z, Brinar M, Van-Lierop L, Barreiro de Acosta M, Zaborowka M, Pugliese D, Cuccia G, Kopylov U. The outcomes of patients treated with 2nd and 3rd line biological in perianal Crohn's disease (PCD) – A multicentre propensity score matched study. *UEG J* 2023; 11 (S8): A361

116. Chalakatevaki K, Kokkotis G, Chatzinikolaou ML, Anagnostopoulou E, Argiriou K, Viazis N, Galanopoulos M, Gerasimatos G, Giouleme O, Zampeli E, Zacharopoulou E, Theodoropoulou A, Kalogirou MS, Karatzas P, **Karmiris K**, Kapsoritakis AN, Koustenis KR, Koutroumpakis I, Kiriakos N, Lazou D, Liatsos C, Mantaka A, Mantzaris GJ, Michalopoulos G, Michopoulos S, Orfanidou A, Papathanasiou E, Polymeros D, Potamianos S, Soufleris K, Tzouvala M, Foteinogiannopoulou K, Chatzidakis A, Psistakis A, Bamias G. Preliminary data on the efficacy of ustekinumab in patients with ulcerative colitis in a “real-world” clinical setting. *UEG J* 2023; 11 (S8): A987-988

117. Papathanasiou E, Kokkotis G, Axiaris G, Viazis N, Giouleme O, Argyropoulos T, Gatopoulou A, Theodoulou A, Theocharis G, Theodoropoulou A, Kalogirou M, Karatzas P, Katsanos KH, **Karmiris K**, Kourikou A, Koutroubakis IE, Liatsos C, Mantzaris GJ, Mathou N, Bellou G, Michalopoulos G, Mantaka A, Nicolaou P, Oikonomou M, Polymeros D, Papatheodoridis G, Stergiou E, Soufleris K, Skouloudis E, Tzouvala M, Tsiolakidou G, Tsironi E, Tsafarakis S, Foteinogiannopoulou K, Chalakatevaki K, Christidou A, Christodoulou DK, Bamias G, Michopoulos S, Zampeli E. Prergrnancy outcomes in patients with inflammatory bowel disease: retrospective data from a Greek national registry. *UEG J* 2023; 11 (S8): A992-993

118. Zacharopoulou E, Viazis N, Psistakis A, Theodoropoulou A, Drygiannakis I, **Karmiris K**, Koutroubakis I, Kevrekidou P, Soufleris K, Katsaros M, Giouleme O, Fousekis F, Katsanos KH, Christodoulou DK, Gaki A, Bamias G, Papathanasiou E, Zampeli E, Michopoloulos S, Liatsos C, Kyriakos N, Veretanos C, Kapsoritakis AN, Argyriou K, Tribonias G, Mantzaris GJ, Tzouvala M. “Real-world” preliminary data on the efficacy and safety of 16-week induction therapy with tofacitinib in patients with ulcerative colitis. *UEG J* 2023; 11 (S8): A1023-1024

119. Chalakatevaki K, Kokkotis G, Chatzinikolaou M.L, Anagnostopoulou E, Argiriou K, Viazis N, Galanopoulos M, Gerasimatos G, Giouleme O, Zampeli E, Zacharopoulou E, Theodoropoulou A, Theocharis G, Kalogirou M, Karatzas P, **Karmiris K**, Kapsoritakis A, Koustenis K, Koutroubakis I, Kyriakos N, Lazou D, Liatsos C, Mantaka A, Mantzaris G, Michalopoulos G, Michopoulos S, Orfanidou A, Papathanasiou E, Polymeros D, Potamianos S, Sotiropoulos C, Soufleris K, Tzouvala M, Foteinogiannopoulou K, Chatzidakis A, Psistakis A, Bamias G. Real-word data on outcomes of treatment with ustekinumab in patients with ulcerative colitis. *J Crohns Colitis* 2024; 18 (Suppl. 1): i1705

14^E ORAL PRESENTATIONS / POSTERS IN INTERNATIONAL MEETINGS

1. Koutroubakis IE, Xidakis C, **Karmiris K**, Sfiridaki A, Kandidaki E, Kouroumalis EA. Serum angiogenin in inflammatory bowel disease. *12th United European Gastroenterology Week (UEGW), Prague 2004*

2. **Karmiris K**, Koutroubakis IE, Drygiannakis D, Makreas S, Drygiannakis I, Kiagiadaki C, Kouroumalis EA. Pancreatic autoantibodies in Greek patients with inflammatory bowel disease. *Falk Symposium No 147, Birmingham 2005*

3. **Karmiris K**, Koutroubakis IE, Drygiannakis D, Makreas S, Drygiannakis I, Kiagiadaki C, Kouroumalis EA. Pancreatic autoantibodies are a specific marker for inflammatory bowel disease. *13th UEGW, Copenhagen 2005*

4. Koutroubakis IE, **Karmiris K**, Makreas S, Xidakis, Kouroumalis EA. Effectiveness of darbepoetin alfa in patients with inflammatory bowel disease and refractory anaemia. *13th UEGW, Copenhagen 2005*
5. Koutroubakis IE, Xidakis C, **Karmiris K**, Sfiridaki A, Kandidaki E, Kouroumalis EA. A potential role of soluble angiopoietin-2 and angiopoietin receptor Tie-2 in inflammatory bowel disease. *Digestive Diseases Week (DDW), Los Angeles 2006*
6. Koutroubakis IE, **Karmiris K**, Makreas S, Xidakis C, Tsiolakidou G, Kouroumalis EA. Effectiveness of darbepoetin alfa, in combination with intravenous iron sucrose, in patients with inflammatory bowel disease and refractory anaemia. *DDW, Los Angeles 2006*
7. **Karmiris K**, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin and ghrelin in inflammatory bowel diseases. *DDW, Los Angeles 2006*
8. Stathaki M, Koutroubakis I, Koukouraki S, **Karmiris K**, Kouroumalis E, Karkavitsas N. Active inflammatory bowel disease: head-to-head comparison between ^{99m}Tc-HMPAO-WBC and ^{99m}Tc (V) DMSA scintigraphy. *Annual Congress of the European Association of Nuclear Medicine, Athens 2006*
9. **Karmiris K**, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Effect of Infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. *14th UEGW, Berlin 2006*
10. Stathaki M, Koutroubakis IE, Koukouraki S, **Karmiris K**, Kouroumalis EA, Karkavitsas N. Active inflammatory bowel disease: head-to-head comparison between ^{99m}Tc-HMPAO-WBC and ^{99m}Tc (V) DMSA scintigraphy. *14th UEGW, Berlin 2006*
11. Koutroubakis IE, **Karmiris K**, Xidakis C, Polychronaki M, Kouroumalis E. Effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. *2nd ECCO Congress, Innsbruck 2007*
12. **Karmiris K**, Koutroubakis IE, Moschandreass J, Kouroumalis EA. Prospective registration and validation of possible risk factors of relapse in patients with inflammatory bowel disease (IBD). *Falk Symposium No 159, Istanbul 2007*
13. **Karmiris K**, Koutroubakis IE, Xidakis C, Polychronaki M, Kouroumalis EA. Effect of infliximab on circulating levels of leptin, adiponectin and resistin in inflammatory bowel disease. *DDW, Washington DC 2007*
14. Stathaki M, Koutroubakis IE, Koukouraki S, **Karmiris K**, Kouroumalis EA, Karkavitsas N. Active inflammatory bowel disease: head-to-head comparison between ^{99m}Tc-HMPAO-WBC and ^{99m}Tc (V) DMSA scintigraphy. *DDW, Washington DC 2007*
15. **Karmiris K***, Noman M, Schnitzler F, Fidder H, Koutroubakis IE, Kouroumalis EA, Vermeire S, Van Assche G, Rutgeerts P. Long-term efficacy and safety of adalimumab treatment in a single-center cohort of Crohn's disease patients who failed to infliximab treatment. *20th Belgian Week of Gastroenterology, Antwerp 2008*
16. **Karmiris K**, Paintaud G, Degenne D, Ferrante M, Duveau A, Noman M, Van Assche G, Vermeire S, Rutgeerts P. Adalimumab trough serum levels and clinical response in a single-center cohort of inflammatory bowel disease patients: can trough serum levels serve as a predictor for future loss of response? *3rd Congress of ECCO, Lyon 2008*
17. **Karmiris K**, Noman M, Schnitzler F, Fidder H, Koutroubakis IE, Kouroumalis EA, Vermeire S, Van Assche G, Rutgeerts P. Long-term efficacy and safety of adalimumab treatment in a single-center cohort of Crohn's disease patients who failed to infliximab treatment. *3rd Congress of ECCO, Lyon 2008*
18. **Karmiris K**, Noman M, Paintaud G, Ferrante M, Duveau A, Degenne D, Van Assche G, Vermeire S, Rutgeerts P. A 3-week course of 80mg weekly administered adalimumab as a rescue therapy for patients with Crohn's disease who lost response to 40mg weekly: relationship with adalimumab trough serum levels. *3rd Congress of ECCO, Lyon 2008*
19. **Karmiris K***, Paintaud G, Degenne D, Ferrante M, Duveau AC, Noman M, Van Assche G, Vermeire S, Rutgeerts P. Adalimumab trough serum levels and clinical response in a single-center cohort of inflammatory bowel disease patients: can trough serum levels serve as a predictor for future loss of response? *DDW, San Diego 2008*

20. **Karmiris K**, Noman M, Paintaud G, Ferrante M, Duveau AC, Degenne D, Van Assche G, Vermeire S, Rutgeerts P. A 3-week course of 80mg weekly administered adalimumab as a rescue therapy for patients with Crohn's disease who lost response to 40mg weekly: relationship with adalimumab trough serum levels. *DDW, San Diego 2008*
21. **Karmiris K**, Noman M, Schnitzler F, Fidder H, Koutroubakis IE, Kouroumalis EA, Vermeire S, Van Assche G, Rutgeerts P. Long-term efficacy and safety of adalimumab treatment in a single-center cohort of Crohn's disease patients who failed to infliximab treatment. *DDW, San Diego 2008*
22. **Karmiris K***, Vanbeckevoort D, Bielen D, Vermeire S, Rutgeerts P, Van Assche G. Baseline magnetic resonance imaging predicts surgery in perianal Crohn's disease patients treated with infliximab: results from a long-term follow-up study. *16th UEGW, Vienna 2008*
23. **Karmiris K***, Noman M, Vermeire S, Van Assche G, Rutgeerts P. Efficacy and safety of adalimumab in ulcerative colitis patients who failed infliximab treatment. *16th UEGW, Vienna 2008*
24. **Karmiris K***, Paintaud G, Degenne D, Duveau AC, Noman M, Van Assche G, Vermeire S, Rutgeerts P. Antibodies against adalimumab in Crohn's disease patients who failed infliximab treatment: correlation with clinical response and trough serum levels. *16th UEGW, Vienna 2008*
25. **Karmiris K**, Noman M, Vermeire S, Van Assche G, Rutgeerts P. Efficacy of adalimumab on extra-intestinal manifestations in patients with inflammatory bowel disease. *16th UEGW, Vienna 2008*
26. **Karmiris K**, Noman M, Vermeire S, Van Assche G, Rutgeerts P. Dose de-escalation in patients with inflammatory bowel disease treated long-term with adalimumab 40mg weekly. *16th UEGW, Vienna 2008*
27. **Brinar M***, De Hertogh G, **Karmiris K**, Cleynen I, Van Assche G, Geboes K, Rutgeerts P, Vermeire S. Allelic variations of autophagy-related 16-like 1 gene and immunity related guanosine phosphatase gene and granuloma formation in patients with Crohn's disease. *16th UEGW, Vienna 2008*
28. **Oustamanolakis PI***, Koutroubakis I, Malliaraki N, **Karmiris K**, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis E. Effects of TNF-alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. *16th UEGW, Vienna 2008*
29. **Tribonias G***, Konstantinidis K, Theodoropoulou A, Vardas E, **Karmiris K**, Chlouverakis G, Paspatis GA. Comparison of standard versus high definition colonoscopy for polyp detection: a randomised controlled trial. *BSG Annual Meeting, Glasgow 2009*
30. Tribonias G, Konstantinidis K, Vardas E, Theodoropoulou A, Zois E, **Karmiris K**, Chlouverakis G, **Paspatis GA**. Comparison of standard versus high definition colonoscopy for polyp detection: a randomised controlled trial. *DDW, Chicago 2009*
31. Tribonias G, Theodoropoulou A, **Konstantinidis K**, Vardas E, **Karmiris K**, Vidaki A, Chroniaris N, Chlouverakis G, Paspatis GA. Comparison of standard versus high definition colonoscopy for polyp detection: a randomised controlled trial. *17th UEGW, London 2009*
32. Oustamanolakis P, **Koutroubakis IE**, Drygiannakis D, **Karmiris K**, Karampasi A, Bourikas L, Kouroumalis EA. Antiglycan antibodies in Greek patients with inflammatory bowel diseases. *5th Congress of ECCO, Prague 2010*
33. Tribonias G, **Konstantinidis K**, Theodoropoulou A, Vardas E, **Karmiris K**, Manolaraki M, Chlouverakis G, Paspatis GA. Deep sedation compared with moderate sedation in polyp detection during colonoscopy: a randomized controlled trial. *DDW, New Orleans 2010*
34. Tribonias G, **Konstantinidis K**, Theodoropoulou A, Vardas E, **Karmiris K**, Manolaraki M, Chlouverakis G, Paspatis GA. Deep sedation compared with moderate sedation in polyp detection during colonoscopy: a randomized controlled trial. *18th UEGW, Barcelona 2010*

35. Ferrante M^{*}, **Karmiris K**, Compennolle G, Ballet V, Vermeire S, Noman M, Rutgeerts P, Gils A, Van Assche G. Efficacy of adalimumab in patients with ulcerative colitis: restoration of serum levels after dose escalation results in a better long-term outcome. *19th UEGW, Stockholm 2011*
36. Ternant D, **Karmiris K**, Van Assche G, Vermeire S, Rutgeerts P, Painsaud G. Adalimumab pharmacokinetics and concentration-effect relationship in Crohn's disease. *7eme Congres de Physiologie de Pharmacologie et de Therapeutique, Dijon 2012*
37. Voudoukis E, **Karmiris K**, Oustamanolakis P, Charitakis A, Archontakis Z, Giannakopoulou K, Theodoropoulou A, Sfiridaki A, Paspatis G, Koutroubakis I. Thrombocytosis and iron deficiency in inflammatory bowel disease patients: a mutual relationship. *20th UEGW, Amsterdam 2012*
38. Voudoukis E, **Karmiris K**, Oustamanolakis P, Theodoropoulou A, Charitakis A, Archontakis Z, Giannakopoulou K, Sfiridaki A, Paspatis G, Koutroubakis I. Thrombocytosis and iron deficiency in inflammatory bowel disease patients: a mutual relationship. *8th Congress of ECCO, Vienna 2013*
39. **Karmiris K**, Voudoukis E, Paspatis GA. Efficacy of vaccination against hepatitis A and B in inflammatory bowel disease patients: preliminary results. *8th Congress of ECCO, Vienna 2013*
40. Voudoukis E, Tavernaraki A, Theodoropoulou A, **Karmiris K**, Vardas E, Giannakopoulou K, Paspatis GA. Split dose bowel preparation in detecting high risk patients for colon neoplasia: a prospective study (preliminary results). *21st UEGW, Berlin 2013*
41. **Karmiris K**, Avgerinos A, Tavernaraki A, Mantzaris GJ, Koukouratos T, Oikonomou K, Kostas A, Viazis N, Kapsoritakis A, Bamias G, Theodoropoulou A, Karamanolis DG, Koutroubakis IE. Prevalence and characteristics of extra-intestinal manifestations in a Greek population of inflammatory bowel disease patients followed-up in tertiary centers. *9th Congress of ECCO, Copenhagen 2014*
42. **Karmiris K**, Avgerinos A, Tavernaraki A, Mantzaris GJ, Koukouratos T, Oikonomou K, Kostas A, Viazis N, Kapsoritakis A, Bamias G, Theodoropoulou A, Karamanolis DG, Koutroubakis IE. Prevalence and characteristics of dermatologic manifestations in a Greek population of inflammatory bowel disease patients followed-up in tertiary centers. *9th Congress of ECCO, Copenhagen 2014*
43. **Karmiris K**, Voudoukis E, Choustoulaki M, Sfiridaki A, Paspatis GA. Efficacy of vaccination against hepatitis A and B in inflammatory bowel disease patients. *9th Congress of ECCO, Copenhagen 2014*
44. **Karmiris K**, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, Oikonomou K, Kostas A, Zampeli E, Papadopoulos V, Theodoropoulou A, Viazis N, Polymeros D, Michopoulos S, Bamias G, Kapsoritakis A, Karamanolis DG, Mantzaris G, Tzathas C, Koutroubakis IE. Hepatobiliary, pancreatic and renal manifestations in Greek inflammatory bowel disease patients. *22nd UEGW, Vienna 2014*
45. Kopylov U, Katsanos K, Van Der Woude CJ, **Karmiris K**, Hernandez V, Odes S, Papamichael K, Koutroubakis I, Bojic D, Kaimakliotis I, Papageorgiou N, Pineda JR, Strongili K, Sanroman L, Mantzaris G, Jovic N, Paspatis G, Christodoulou DK, Ben-Horin S, Tsianos EV. Safety and tolerability of methotrexate in inflammatory bowel disease – a multicenter european cohort study. *23rd UEGW, Barcelona 2015*
46. Kopylov U, Katsanos K, Van Der Woude CJ, **Karmiris K**, Hernandez V, Odes S, Papamichael K, Koutroubakis I, Bojic D, Kaimakliotis I, Papageorgiou N, Pineda JR, Strongili K, Sanroman L, Mantzaris G, Jovic N, Paspatis G, Christodoulou DK, Ben-Horin S, Tsianos EV. Methotrexate for maintenance of remission in Crohn's disease – a multicenter european cohort study. *23rd UEGW, Barcelona 2015*
47. Fiorino G^{*}, Ellul P, Muscat M, Karatzas P, Silva M, Peixoto A, Felice C, Bossa F, Lakatos PL, Sebastian S, Ungar B, Furfaro F, **Karmiris K**, Katsanos KH, Navarro Cortes P, Bosca Watts MM, Christodoulou DK, Maconi G, Kopylov U, Armuzzi A, Magro F, Mantzaris G, Ben-Horin S, Danese S. Infliximab discontinuation is associated with a higher risk for relapse in

patients with ulcerative colitis in remission: a multinational collaborative retrospective study. 11th Congress of ECCO, Amsterdam 2016

48. Fiorino G*, Ellul P, Muscat M, Karatzas P, Silva M, Peixoto A, Felice C, Bossa F, Lakatos PL, Sebastian S, Ungar B, Furfaro F, **Karmiris K**, Katsanos KH, Navarro Cortes P, Bosca Watts MM, Christodoulou DK, Maconi G, Kopylov U, Armuzzi A, Magro F, Mantzaris G, Ben-Horin S, Danese S. Infliximab discontinuation is associated with a higher risk for relapse in patients with ulcerative colitis in remission: a multinational collaborative retrospective study. *DDW, San Diego 2016*

49. Fiorino G, Navarro Cortes P, Ellul P, Felice C, Karatzas P, Silva M, Lakatos PL, Bossa F, Sebastian S, Ungar B, Furfaro F, **Karmiris K**, Katsanos KH, Muscat M, Christodoulou DK, Maconi G, Kopylov U, Magro F, Mantzaris G, Armuzzi A, Bosca Watts MM, Ben-Horin S, Bonovas S, Danese S. Discontinuation of infliximab in patients with ulcerative colitis is associated with increased risk of relapse: a multinational retrospective cohort study. *BSG Annual Meeting, Liverpool 2016*

50. Fragkaki M, Bachlitzanaki M, **Karmiris K**, Theodoropoulou A, Vardas E, Paspatis G. Inflammatory bowel disease and colorectal cancer: interim analysis of a single center retrospective chart review. 24th UEGW, Vienna 2016

51. Chaparro M*, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Avni Biron I, Lopez-Serrano P, Casanova M, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Bar-Gil Shitrit A, Gutierrez A, Doherty G, Fernandez-Salazar L, Cadilla Martinez J, Huguet J, O'Toole A, Stasi E, Mancenido Marcos N, Villoria A, **Karmiris K**, Rahier J, Rodriguez C, Diz-Lois Palomares M, Fiorino G, Benitej J, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Ferrer Bradley I, Lopez-San Roman A, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, Van Hoeve K, Torres P, Gravito-Soares E, Rudbeck-Thomsen D, Bartolo O, Peixoto A, Martin G, Perez J, Garre A, Donday MG, Martin de Capri J, Gisbert JP, Gastroenterology Units, on behalf of the TEDDY study group investigators. Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY study. 12th Congress of ECCO, Barcelona 2017

52. Sebastian S, Black C, Nair MV, Drskova T, Hradsky O, Tzivnikos C, Sahnan K, Muhammed R, Devadason D, Parmar RS, Crook K, Akbar A, Thomson M, Pugliese D, Armuzzi A, Katsanos KH, Christodoulou DK, Selinger C, Maconi G, Fiorino G, Kopylov U, Bosca-Watts MM, **Karmiris K**, Ellul P, Ben-Horin S, Danese S, Hart AL. Differences in therapeutic approaches and outcomes in paediatric and adult onset Crohn's disease with perianal fistula: comparison of 2 multicenter fistula cohorts. 12th Congress of ECCO, Barcelona 2017

53. Black C, Pugliese D, Sahnan K, Armuzzi A, Elkady SM, Hart AL, Katsanos KH, Christodoulou DK, Selinger C, Maconi G, Fiorino G, Davidov Y, Kopylov U, Ben-Horin S, Navarro P, Bosca-Watts MM, Muscat M, Ellul P, **Karmiris K**, Allgar V, Danese S, Fearnhead N, Sebastian S. Presentation and surgical interventions for Crohn's disease with perianal fistula in the biologics era: results from a multicentre study. 12th Congress of ECCO, Barcelona 2017

54. Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, **Karmiris K**, Cheon JH, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen M, Har-Noy O, Bernstein CN. Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practice. 12th Congress of ECCO, Barcelona 2017

55. Sebastian S, Black C, Pugliese D, Armuzzi A, Sahnan K, Elkady SM, Katsanos KH, Christodoulou DK, Selinger C, Maconi G, Fiorino G, Kopylov U, Davidov Y, Bosca-Watts MM, Ellul P, Muscat M, **Karmiris K**, Fearnhead NS, Allgar V, Hart AL, Ben-Horin S, Danese S. Multicenter cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula. 12th Congress of ECCO, Barcelona 2017

56. Fragaki M, Bachlitzanaki M, **Karmiris K**, Theodoropoulou A, Vardas E, Paspatis G. Inflammatory bowel disease and colorectal cancer: analysis of a single center retrospective chart review. 12th Congress of ECCO, Barcelona 2017

57. Shaji S, Black C, Pugliese D, Selinger C, Sahnun K, Hart A, Katsanos K, Christodoulou D, Maconi G, Fiorino G, Kopylov U, Davidov Y, Bosca-Watts MM, Muscat M, Ellul P, **Karmiris K**, Allgar V, Fearnhead N, Armuzzi A, Ben-Horin S, Danese S. Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula. *DDW, Chicago 2017*
58. Shaji S, Black C, Pugliese D, Armuzzi A, Sahnun K, Katsanos K, Christodoulou D, Selinger C, Maconi G, Fiorino G, Kopylov U, Davidov Y, Allgar V, Bosca-Watts MM, Ellul P, **Karmiris K**, Ben-Horin S, Hart A, Fearnhead N, Danese S. Presentation and surgical interventions for Crohn's disease with perianal fistula in the biologics era: results from a multicentre study. *DDW, Chicago 2017*
59. Papastergiou V, Fragaki M, Dimas I, Vardas E, Theodoropoulou A, Mathou N, Giannakopoulos A, **Karmiris K**, Apessou D, Giannikaki L, Chlouverakis G, Paraskeva K, Paspatis G. Randomized comparison of injection-assisted cold snare polypectomy versus endoscopic mucosal resection for small (6-10mm) colorectal polyps. *DDW, Chicago 2017*
60. Tzivnikos C, Nair MV, Ashton K, Drskova T, Sahnun K, Muhammed R, Devadason D, Hradsky O, Crook K, Palmer R, Akbar A, Thomson M, Hart A, Fiorino G, Black C, Pugliese D, Armuzzi A, Katsanos K, Christodoulou D, Maconi G, Selinger C, Kopylov U, Bosca-Watts M, **Karmiris K**, Ellul P, Ben-Horin S, Danese S, Sebastian S. Differences in therapeutic approaches and outcomes in paediatric and adult onset Crohn's disease with perianal fistula: comparison of 2 ECCO collaborative multicenter fistula cohorts. *BSG Annual Meeting Manchester 2017*
61. Black C, Pugliese D, Sahnun K, Hart A, Fiorino G, Armuzzi A, Katsanos K, Christodoulou D, Selinger C, Maconi G, Kopylov U, Bosca-Watts M, **Karmiris K**, Myers S, Davidov Y, Ellul P, Ben-Horin S, Danese S, Fearnhead N, Sebastian S. Presentation and surgical interventions for Crohn's disease with perianal fistula in the biologics era: results from a multicentre study. *BSG Annual Meeting Manchester 2017*
62. Papastergiou V, Fragaki M, Dimas I, Mpitouli A, Vardas E, Theodoropoulou A, Mathou N, Giannakopoulos A, **Karmiris K**, Apessou D, Giannikaki L, Chlouverakis G, Paraskeva K, Paspatis G. Cold snare polypectomy with submucosal pre-lift versus endoscopic mucosal resection for 6-10mm colorectal polyps: a randomized non-inferiority trial. 25th *UEGW, Barcelona 2017*
63. Fragaki M, Mpitouli A, Dimas I, Paspatis G, **Karmiris K**. Tuberculin skin test conversion rate in inflammatory bowel disease patients receiving anti-TNFalpha agents. 25th *UEGW, Barcelona 2017*
64. Fragaki M, Chliara E, Dimas I, Mpitouli A, Vardas E, Theodoropoulou A, **Karmiris K**, Voudoukis E, Giannikaki L, Paspatis G. Complete endoscopic mucosal resection of malignant colonic sessile polyps and clinical outcome of 51 cases. 25th *UEGW, Barcelona 2017*
65. Fragaki M, Chliara E, Dimas I, Mpitouli A, Vardas E, Theodoropoulou A, **Karmiris K**, Voudoukis E, Giannikaki L, Paspatis G. Complete endoscopic mucosal resection of malignant colonic sessile polyps and clinical outcome of 51 cases. 25th *UEGW, Barcelona 2017*
66. Gatt K, Schembri J, Katsanos KH, Christodoulou DK, Balomenos D, **Karmiris K**, Pontas C, Kopylov U, Koutroubakis I, Foteinogiannopoulou K, Fabian A, Molnar T, Zammit D, Ellul P, Mantzaris GJ. Levels of engagement in physical activity and fatigue in IBD patients. 13th *Congress of ECCO, Vienna 2018*
67. Schembri J, Gatt K, Katsanos KH, Christodoulou DK, Balomenos D, **Karmiris K**, Pontas C, Kopylov U, Koutroubakis I, Foteinogiannopoulou K, Fabian A, Molnar T, Zammit D, Ellul P, Mantzaris GJ. A study on the impact of diagnosis on the level of exercise amongst patients with IBD. 13th *Congress of ECCO, Vienna 2018*
68. Fragaki M, Paspatis G, **Karmiris K**. Tuberculin skin test conversion rate in inflammatory bowel disease patients receiving anti-TNFa agents. 13th *Congress of ECCO, Vienna 2018*
69. Mantaka A, Tsoukali E, Fragaki M, **Karmiris K**, Viazis N, Mantzaris G, Koutroubakis I. Disease severity in patients with inflammatory bowel disease associated with cardiovascular diseases. 13th *Congress of ECCO, Vienna 2018*

70. Viazis N, Pontas C, Belesioutou E, **Karmiris K**, Dimas I, Fragaki M, Paspatis G, Banasa M, Drygiannakis I, Koutroubakis I, Maraki S, Moschovis D, Tzouvala M, Kouskoumpekou F, Theocharis G, Tsolias C, Thomopoulos K, Apostolopoulos G, Stamouli V, Zampeli E, Axiaris G, Michopoulos S, Prifti H, Mantzaris GJ. Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece. *13th Congress of ECCO, Vienna 2018*
71. Fragaki M, Voudoukis E, Chliara E, Dimas I, Mpitouli A, Vardas E, Theodoropoulou A, **Karmiris K**, Giannikaki L, Paspatis G. Complete endoscopic mucosal resection of malignant colonic sessile polyps and clinical outcome of 51 cases. *ESGE days, Budapest 2018*
72. Fragaki M, Voudoukis E, Chliara E, Dimas I, Mpitouli A, Vardas E, Theodoropoulou A, **Karmiris K**, Velegaki M, Giannikaki L, Paspatis G. Complete endoscopic mucosal resection of malignant colonic sessile polyps and clinical outcome of 51 cases. *DDW, Washington DC 2018*
73. Mantaka A, Tsoukali E, Fragaki M, **Karmiris K**, Viazis N, Mantzaris G, Koutroubakis I. Disease severity in patients with inflammatory bowel disease associated with cardiovascular diseases. *26th UEGW, Vienna 2018*
74. Rodrigues R, Sladek M, Katsanos K, Van der Woude CJ, Wei J, Teich N, Ellul P, Savarino E, Chaparro M, Beaton D, Oliveira AM, Fragaki M, Shitrit Bar-Gil A, Ramos L, **Karmiris K**. Oesophageal Crohn's disease: diagnosis and outcome of an ECCO-CONFERENCE case series. *14th Congress of ECCO, Copenhagen 2019*
75. Fragaki M, Pasparaki E, Bibaki E, Kounalakis G, Ferdoutsis E, Paspatis G, Meletis G, **Karmiris K**. Pulmonary function tests in asymptomatic patients with inflammatory bowel disease: preliminary results of a single-center cohort study. *14th Congress of ECCO, Copenhagen 2019*
76. Lisle J, Myers S, Pugliese D, Raine T, de Vries AC, Katsanos K, Filip R, **Karmiris K**, Sebastian S. Drug induced liver injury (DILI) secondary to biologic therapy in IBD: ECCO-CONFERENCE series. *14th Congress of ECCO, Copenhagen 2019*
77. Mantaka A, Tsoukali E, Fragaki M, **Karmiris K**, Viazis N, Mantzaris G, Koutroubakis I. Association between the use of antihypertensive agents and disease severity in patients with inflammatory bowel disease. *14th Congress of ECCO, Copenhagen 2019*
78. Dimas I, Voudoukis E, Paspatis G, **Karmiris K**. Efficacy of vaccination against hepatitis A in inflammatory bowel disease: a single-centre cohort study. *14th Congress of ECCO, Copenhagen 2019*
79. Dimas I, Voudoukis E, Paspatis G, **Karmiris K**. Post-vaccination kinetics of antibodies against hepatitis B surface antigen in inflammatory bowel disease patients: a single-center cohort study. *14th Congress of ECCO, Copenhagen 2019*
80. Dimas I, **Karmiris K**. Efficacy of vaccination against hepatitis A in inflammatory bowel disease patients: a single center cohort study. *24th Congress of Balkan Military Medical Committee, Tirana 2019*
81. Mantaka A, Tsoukali E, Fragaki M, **Karmiris K**, Viazis N, Mantzaris GJ, Koutroubakis IE. Association between the use of antihypertensive agents and disease severity in patients with inflammatory bowel disease. *DDW, San Diego 2019*
82. Mantzaris GJ, Theodoropoulou A, **Karmiris K**, Koutroubakis IE, Orfanoudaki E, Katsanos K, Xourgias V, Michalopoulos G, Tzouvala M, Moschovis D, Michopoulos S, Zampeli E, Soufleris K, Kafalis N, Ilias A, Stefanidis E, Chatzievangelinou C, Kyriakakis A, Zeglinas C. A retrospective study to examine the impact of Crohn's disease duration on adalimumab's effectiveness to achieve remission in patients bearing poor prognostic factors: the "MODIFY" study. *DDW, San Diego 2019*
83. **Karmiris K**, Dimas I, Voudoukis E, Paspatis G. Efficacy of vaccination against hepatitis A in inflammatory bowel disease patients: a single-center cohort study. *Falk Symposium No 215, St Petersburg 2019*
84. Fragaki M, Pasparaki E, Bibaki E, Kounalakis G, Theodoropoulou A, Ferdoutsis E, Paspatis G, Meletis G, **Karmiris K**. Pulmonary function tests in asymptomatic patients with inflammatory bowel disease: preliminary results of a single center cohort study. *27th UEGW, Barcelona 2019*

85. [Phillips E](#), Verstockt B, Ribaldone D, Guerra I, Teich N, Katsanos K, Filip R, Molner T, **Karmiris K**. Extranodal primary intestinal lymphoma in inflammatory bowel disease: an ECCO CONFER multi-center case series. *15th Congress of ECCO, Vienna 2020*
86. **Karmiris K**, Fotinogiannopoulou K, Velegraki M, Koureta E, Axaris G, Kateri C, Kokkotis G, Kapizioni C, Markopoulos P, Katsoula A, Gklavas A, Papaconstantinou I, Giouleme O, Tsironi E, Michalopoulos G, Bamias G, Papadopoulos V, Kapsoritakis A, Zampeli E, Michopoulos S, Karatzas P, Papatheodoridis G, Theodoropoulou A, Koutroubakis IE. Prevalence and management of anemia in Greek patients with inflammatory bowel disease: a multicentre real-life cohort study. *15th Congress of ECCO, Vienna 2020*
87. [Phillips E](#), Verstockt B, Sladek M, de Boer N, Katsanos K, **Karmiris K**, Albshesh A, Eriksson C, Bergemalm D, Molner T, Ellul P. Orofacial granulomatosis in Crohn's disease: an ECCO CONFER multi-center case series. *15th Congress of ECCO, Vienna 2020*
88. [Albshesh A](#), Taylor J, Savarino EV, Truyens M, Armuzzi A, Ribaldone DG, Shitrit A, Fibelman M, Molander P, Liefferinckx C, Nancy S, Korani M, Farkas K, Barreiro de Acosta M, Domislovic V, Suris G, Eriksson C, Alves C, Mpitouli A, Jiang CD, Tepeš K, Coletta M, Foteinogiannopoulou K, Afif W, Marinelli C, Lobaton Ortega T, Pugliese D, Maharshak N, Cremer A, Limdi JK, Molnár T, Otero-Alvarin B, Krznaric Z, Magro F, **Karmiris K**, Raine T, Drobne D, Koutroubakis I, Kopylov U. Effectiveness of third-class biologic treatment in Crohn's disease: a multi-center retrospective cohort study. *28th UEGW, virtual 2020*
89. [Fragaki M](#), Velegraki M, Mpitouli A, Nikolaou P, Tribonias G, Voudoukis E, **Karmiris K**, Theodoropoulou A, Vardas E, Paspatis G. A paradigm shift in the management of acute iatrogenic colonic perforations: a 24-year retrospective comprehensive study. *ESGE days 2021*
90. [Fragaki M](#), Velegraki M, Mpitouli A, Nikolaou P, Tribonias G, Voudoukis E, **Karmiris K**, Theodoropoulou A, Vardas E, Paspatis G. A paradigm shift in the management of acute iatrogenic colonic perforations: a 24-year retrospective comprehensive study. *DDW, virtual 2021*
91. [Bamias G](#), Kokkotis G, Christodoulou D, Delis V, Gatopoulou A, Giouleme O, Kalantzis C, Kapsoritakis A, Karatzas P, **Karmiris K**, Katsanos K, Kevrekidou P, Mathou N, Michalopoulos G, Michopoulos S, Papaconstantinou I, Polymeros D, Potamianos S, Pouloupoulos G, Protopappas A, Soufleris K, Theodoropoulou A, Triantafyllidis JK, Triantafyllou K, Tsiolakidou G, Tsironi E, Tzouvala M, Viazis N, Zacharopoulou E, Zampeli E, Papatheodoridis G, Mantzaris GJ. The natural history of COVID-19 in patients with IBD: A nationwide study by the Hellenic Society for the Study of IBD. *16th Congress of ECCO, virtual 2021*
92. [Sciberras M](#), Nascimento C, Tabone T, **Karmiris K**, Nikolaou P, Theodoropoulou A, Mula A, Goren I, Yanai H, Amir H, Mantzaris G, Georgiadi T, Foteinogiannopoulou K, Koutroubakis I, Allocca M, Fiorino G, Furfaro F, Katsanos KH, Fousekis F, Michalopoulos G, Torres J, Ellul P. Effects of Covid-19 on employment in IBD patients. *16th Congress of ECCO, virtual 2021*
93. [Sciberras M](#), Nascimento C, Tabone T, **Karmiris K**, Nikolaou P, Theodoropoulou A, Mula A, Goren I, Yanai H, Amir H, Mantzaris G, Georgiadi T, Foteinogiannopoulou K, Koutroubakis I, Allocca M, Fiorino G, Furfaro F, Katsanos KH, Fousekis F, Michalopoulos G, Torres J, Ellul P. Mental health, work presenteeism and exercise in IBD patients. *16th Congress of ECCO, virtual 2021*
94. [Sciberras M](#), Nascimento C, Tabone T, **Karmiris K**, Nikolaou P, Theodoropoulou A, Mula A, Goren I, Yanai H, Amir H, Mantzaris GJ, Georgiadi T, Foteinogiannopoulou K, Koutroubakis I, Allocca M, Fiorino G, Furfaro F, Katsanos KH, Fousekis F, Michalopoulos G, Torres J, Ellul P. Effects of COVID-19 on employment in IBD patients. *29th UEGW, virtual 2021*
95. [Sciberras M](#), Nascimento C, Tabone T, **Karmiris K**, Nikolaou P, Theodoropoulou A, Mula A, Goren I, Yanai H, Amir H, Mantzaris G, Georgiadi T, Foteinogiannopoulou K, Koutroubakis I, Allocca M, Fiorino G, Furfaro F, Katsanos KH, Fousekis

F, Michalopoulos G, Torres J, Ellul P. Mental health, work presenteeism and exercise in IBD patients. *29th UEGW, virtual 2021*

96. Bamias G, Kokkotis G, Christidou A, Christodoulou DK, Delis V, Diamantopoulou G, Fessatou S, Gatopoulou A, Giouleme O, Kafritsa Y, Kalantzis C, Kapsoritakis AN, Karatzas P, **Karmiris K**, Katsanos KH, Kevrekidou P, Kosmidis C, Mantaka A, Mathou N, Michalopoulos G, Michopoulos S, Papaconstantinou I, Papatheodoridis G, Polymeros D, Potamianos S, Pouloupoulos G, Protopapas A, Sklavaina M, Soufleris K, Theocharis G, Theodoropoulou A, Thomopoulos K, Triantafyllidis J, Triantafyllou K, Tsiolakidou G, Tsironi E, Tzouvala M, Viazis N, Xourgias V, Zacharopoulou E, Zampeli E, Mantzaris GJ. The natural history of COVID-19 in patients with IBD: a nationwide study by the Hellenic Society for the Study of IBD. *29th UEGW, virtual 2021*

97. Mpitouli A, Nikolaou P, Velegraki M, Psistakis A, Fragaki M, Vardas E, Paspatis G, **Karmiris K**, Theodoropoulou A. Inflammatory bowel disease patients with a first degree relationship bear striking similarities: a retrospective single center observational study. *29th UEGW, virtual 2021*

98. Vella Baldacchino A, Ellul P, Schembri J, Tua J, Molnar T, Resal T, **Karmiris K**, Theodoropoulou A, Fragaki M, Mantzaris G, Tsoukali E, Alloca M, Furfaro F, Moran G, Phillips F, Varyani F, Katsanos K, Fousekis F, Christodoulou D, Sebastian S, Gonzalez HA, Yanai H, Snir Y, Lerner Z, Michalopoulos G. Heavy pseudopolyp burden in inflammatory bowel disease predicts more severe disease: a multicenter cohort study. *29th UEGW, virtual 2021*

99. Katsoula A, Axiaris G, Michopoulos S, Zampeli E, Mpitouli A, Theodoropoulou A, **Karmiris K**, Palatianou M, Tzouvala M, Tribonias G, Christidou A, Mantzaris GJ, Viazis N, Dimitriadis N, Soufleris K, Pachiadakis I, Boubonaris A, Nakos A, Pastras P, Triantos C, Theocharis G, Kourkoulis P, Michalopoulos G, Karatzas P, Papatheodoridis G, Moutzoukis M, Christodoulou D, Katsanos K, Zlatinoudis C, Tsironi E, Philippidis A, Protopappas A, Paraskeva K, Mathou N, Manolakopoulos S, Kourikou A, Kokkotis G, Bamias G, Gklavas A, Papaconstantinou I, Machaira A, Koutroubakis I, Anagnostopoulou E, Mantaka A, Talimtzis P, Giouleme O. The inflammatory bowel disease – disk tool for assessing disability in inflammatory bowel disease patients: validation of the Greek version. *29th UEGW, virtual 2021*

100. Mpitouli A, Nikolaou P, Theodoropoulou A, **Karmiris K**. Association of endoscopic with histologic remission in patients with inflammatory bowel disease in clinical remission treated with anti-TNFα agents. *29th UEGW, virtual 2021*

101. Cheon JH, Ben-Horin S, Har-Noy O, Katsanos K, Roblin X, Cheon MH, Abu-Kaf H, Gao X, Cesarini M, Bojic D, Theodoropoulou A, **Karmiris K**, Knezevic-Ivanovski T, Christodoulou D, Lin X. Combination corticosteroids with 5-ASA versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: a multicenter randomized controlled trial. *Korean DDW, virtual 2021*

102. Ben-Horin S, Har-Noy O, Katsanos KH, Xavier R, Chen MH, Gao X, Schwartz D, Cheon JH, Cesarini M, Bojic D, Protic M, Theodoropoulou A, Abu-Kaf H, Engel T, Tang J, Veyrard P, Lin X, Mao R, Christodoulou D, **Karmiris K**, Knezevic-Ivanovski T. Corticosteroids and 5-ASA versus corticosteroids alone for acute severe ulcerative colitis: a randomized controlled trial. *Crohns & Colitis Congress 2022, virtual*

103. Viazis N, Theodoropoulou A, Zampeli E, **Karmiris K**, Tzouvala M, Bamias G, Koutroubakis I, Liatsos C, Koustenis K, Veretanos C, Papathanasiou E, Zacharopoulou E, Tribonias G, Kitsou V, Drygiannakis I, Michopoulos S, Mantzaris G. The natural history of COVID-19 in vaccinated inflammatory bowel disease patients. *17th Congress of ECCO, virtual 2022*

104. Ben-Horin S, Har-Noy O, Katsanos KH, Xavier R, Chen MH, Gao X, Schwartz D, Cheon JH, Cesarini M, Bojic D, Protic M, Theodoropoulou A, Abu-Kaf H, Engel T, Tang J, Veyrard P, Lin X, Mao R, Christodoulou D, **Karmiris K**, Knezevic-Ivanovski T; ComboMesa. Combination corticosteroids with 5-aminosalicylic acid versus corticosteroids alone in the treatment of hospitalized patients with acute severe ulcerative colitis: a multi-center randomized controlled trial. *17th Congress of ECCO, virtual 2022*

105. Reves J, Abreu B, Chaparro M, Gisbert JP, Alocca M, Fiorino G, Barberio B, Zingone F, Pisani A, Cassar D, Michalopoulos G, Mantzaris G, Mountaki K, Koutroubakis I, **Karmiris K**, Katsanos K, Duricova D, Burisch J, Madsen GR, Maaser C, Naila A, Orfanoudaki E, Milivojevic V, Buisson A, Avedano L, Leone S, Torres J, Ellul P. Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in inflammatory bowel disease patients: an international web-based survey. *17th Congress of ECCO, virtual 2022*
106. Orfanoudaki E, Zacharopoulou E, Kitsou V, **Karmiris K**, Theodoropoulou A, Mantzaris GJ, Tzouvala M, Michopoulos S, Zampeli E, Michalopoulos G, Karatzas P, Viazis N, Liatsos C, Bamias G, Koutroubakis IE. Real world use and adverse events of SARS-CoV-2 vaccination in Greek patients with inflammatory bowel disease. *17th Congress of ECCO, virtual 2022*
107. Zacharopoulou E, Orfanoudaki E, Kitsou V, Tzouvala M, Tribonias G, Mantzaris GJ, Viazis N, Christidou A, Almpani F, **Karmiris K**, Theodoropoulou A, Tsafaridou M, Michopoulos S, Zampeli E, Papathanasiou E, Michalopoulos G, Tigkas S, Karatzas P, Laoudi E, Liatsos C, Kyriakos N, Mylonas I, Theocharis G, Koutroubakis IE, Bamias G. Patients with inflammatory bowel diseases on anti-TNF treatment have impaired antibody production after anti-SARS-CoV-2 vaccination: results from a Panhellenic registry. *17th Congress of ECCO, virtual 2022*
108. Reves J, Abreu BS, Chaparro M, Gisbert JP, Alocca M, Fiorino G, Barberio B, Zingone F, Pisani A, Cassar D, Michalopoulos G, Mantzaris GJ, Mountaki A, Koutroubakis IE, **Karmiris K**, Katsanos K, Duricova D, Burisch JM, Madsen GR, Maaser C, Arebi N, Orfanoudaki E, Milivojevic V, Buisson A, Avedano L, Leone S, Torres J, Ellul P. Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in inflammatory bowel disease patients: an international web-based survey. *DDW, hybrid, San Diego 2022*
109. Orfanoudaki E, Zacharopoulou E, Kitsou V, **Karmiris K**, Theodoropoulou A, Mantzaris GJ, Tzouvala M, Viazis N, Michopoulos S, Zampeli E, Michalopoulos G, Karatzas P, Liatsos C, Bamias G, Koutroubakis IE. Real world use and adverse events of SARS-CoV-2 vaccination in Greek patients with inflammatory bowel disease. *DDW, hybrid, San Diego 2022*
110. Zacharopoulou E, Orfanoudaki E, Kitsou V, Tzouvala M, Tribonias G, Mantzaris GJ, Viazis N, Christidou A, Georgiadi T, **Karmiris K**, Theodoropoulou A, Tsafaridou M, Michopoulos S, Zampeli E, Papathanasiou E, Michalopoulos G, Tigkas S, Karatzas P, Laoudi E, Liatsos C, Kyriakos N, Mylonas I, Theocharis GJ, Kafentzi T, Koutroubakis IE, Bamias G. Patients with inflammatory bowel diseases on anti-TNF treatment have impaired antibody production after anti-SARS-CoV-2 vaccination: results from a Panhellenic registry. *DDW, hybrid, San Diego 2022*
111. Allocca M, Catalano G, Savarino EV, Chaparro Sanchez M, Levartovsky A, Michalopoulos G, Viazis N, Fousekis FS, Psistakis A, Noviello D, Neto do Nascimento C, Caron B, Kitsou V, Bamias G, Garcia MJ, Zacharopoulou E, Foteinogiannopoulou K, D'Amico F, Koutroubakis I, Ellul P, Tzouvala M, Peyrin-Biroulet L, Torres J, Caprioli F, **Karmiris K**, Theodoropoulou A, Katsanos KH, Christodoulou DK, Mantzaris GJ, Kopylov U, Gisbert J, Danese S, Magro F, Fiorino G. Third-line therapy in refractory ulcerative colitis: a comparison between tofacitinib and ustekinumab. *30th UEGW, Vienna 2022*
112. Viazis N, Drygiannakis I, **Karmiris K**, Theodoropoulou A, Zampeli E, Tzouvala M, Bamias G, Liatsos C, Theocharis G, Vrakas S, Tsironi E, Mathou N, Mantaka A, Christidou A, Koustenis KP, Veretanos C, Papathanasiou E, Zacharopoulou E, Tribonias G, Kitsou V, Kartsoli S, Theodoulou A, Michopoulos S, Thomopoulos K, Koutroubakis I, Mantzaris GJ. The natural history of COVID-19 in vaccinated inflammatory bowel disease patients. *30th UEGW, Vienna 2022*
113. Viazis N, Christodoulou DK, Gioulema O, Theodoropoulou A, Bamias G, Zampeli E, Koutroubakis I, Tzouvala M, **Karmiris K**, Mousavere I, Katsanos KH, Katsaros M, Kitsou V, Axiaris G, Michopoulos S, Foteinogiannopoulou K, Zacharopoulou E, Tribonias G, Mountaki K, Mantzaris GJ. Tofacitinib for the treatment of moderate – severe ulcerative colitis: the Greek experience. *30th UEGW, Vienna 2022*

114. Nicolaou P, Theodoropoulou A, Psistakis A, Arna D, Velegraki M, Fragkaki M, **Karmiris K**, Vardas E, Paspatis G. The use of video capsule endoscopy (vce) in patients with a new diagnosis of Crohn's disease: the experience of one center. 18th Congress of ECCO, Copenhagen 2023
115. Foteinogiannopoulou K, Nicolaou P, Mala A, Theodoraki E, Orfanoudaki E, Theodoropoulou A, **Karmiris K**, Koutroubakis I. The prevalence and risk factors for malignancies in patients with inflammatory bowel disease in Crete: a case control study. 18th Congress of ECCO, Copenhagen 2023
116. Nikolaou P, Fragaki M, Psistakis A, Arna D, Velegraki M, **Karmiris K**, Theodoropoulou A, Vardas E, Paspatis G. Inflammatory fibroid polyps (IFPs) of the stomach: a benign tumour with different clinical manifestations. A single center study. ESGE days, Dublin 2023
117. Geldof J, Truyens M, Hanssens M, Van Gucht E, Swietek N, Holvoet T, Rodriguez-Lago I, Elorza A, Bouillon V, Cremer A, Martins V, Argyriou K, Diculescu M, Moens A, Bossuyt P, Theodoraki E, Koutroubakis I, Fernandes SR, Pedro J, **Karmiris K**, Baert F, Ferreira-Iglesias R, Peeters H, Claeys S, Casanova MJ, Eder P, Porter R, Arnott IDR, Karakan T, Mesonero Gismero F, Reves J, Torres J, Van Dyck E, Jauregui-Amezaga A, Manosa Ciria M, Riviere P, Marquez Mosquera L, Portela F, Pimentel R, Lobaton T, PORCSE Study Group. Prophylactic versus endoscopy-driven treatment of Crohn's postoperative recurrence: completed results of a retrospective, multicentric, European study (PORCSE study). 31st UEGW, Copenhagen 2023
118. Goren I, Falleg Boldes O, Boldes T, Knyazev OV, Kagramanova A, Limdi JK, Liu E, Holvoet T, Eder P, Bezzio C, Saibeni S, Vernero M, Alimenti E, Chaparro M, Gisbert J, Orfanoudaki E, Koutroubakis I, Pugliese D, Cuccia G, Calvino Suarez C, Ribaldone DG, Veisman I, Sharif K, Aratari A, Papi C, Mylonas I, Mantzaris GJ, Truyens M, Nancey S, Castiglione F, Nardone OM, Calabrese G, **Karmiris K**, Velegraki M, Theodoropoulou A, Shitrit A, Lukas M, Vojtechova G, Ellul P, Bugeja L, Savarino EV, Dotan I, Yanai H. Outcomes of elderly patients hospitalized for inflammatory bowel disease flare complicated by Clostridioides Difficile infection – The ENTRIT Study Group. 31st UEGW, Copenhagen 2023
119. Shani U, State M, Negreanu L, Mateescu BR, Davidoiu AM, Silva I, Magro F, Lees CW, Plevris N, Roblin X, Castellet Farrus S, Lama YG, Wang S, Abad C, Imperatore N, Lukas M, Vojtechova G, Regev O, Ben-Horin S, Nancey S, Savarino E, Stawczyk-Eder K, Eder P, Toskas A, Kamperidis N, Arebi N, Farkas B, Farkas K, Pipek B, Falt P, **Karmiris K**, Nicolaou P, Krznaric Z, Brinar M, Van-Lierop L, Barreiro de Acosta M, Zaborowka M, Pugliese D, Cuccia G, Kopylov U. The outcomes of patients treated with 2nd and 3rd line biological in perianal Crohn's disease (PCD) – A multicentre propensity score matched study. 31st UEGW, Copenhagen 2023
120. Chalakatevaki K, Kokkotis G, Chatzinikolaou ML, Anagnostopoulou E, Argiriou K, Viazis N, Galanopoulos M, Gerasimatos G, Giouleme O, Zampeli E, Zacharopoulou E, Theodoropoulou A, Kalogirou MS, Karatzas P, **Karmiris K**, Kapsoritakis AN, Koustenis KR, Koutroumpakis I, Kiriakos N, Lazou D, Liatsos C, Mantaka A, Mantzaris GJ, Michalopoulos G, Michopoulos S, Orfanidou A, Papathanasiou E, Polymeros D, Potamianos S, Soufleris K, Tzouvala M, Foteinogiannopoulou K, Chatzidakis A, Psistakis A, Bamias G. Preliminary data on the efficacy of ustekinumab in patients with ulcerative colitis in a “real-world” clinical setting. 31st UEGW, Copenhagen 2023
121. Papathanasiou E, Kokkotis G, Axaris G, Viazis N, Giouleme O, Argyropoulos T, Gatopoulou A, Theodoulou A, Theocharis G, Theodoropoulou A, Kalogirou M, Karatzas P, Katsanos KH, **Karmiris K**, Kourikou A, Koutroubakis IE, Liatsos C, Mantzaris GJ, Mathou N, Bellou G, Michalopoulos G, Mantaka A, Nicolaou P, Oikonomou M, Polymeros D, Papatheodoridis G, Stergiou E, Soufleris K, Skouloudis E, Tzouvala M, Tsiolakidou G, Tsironi E, Tsafarakis S, Foteinogiannopoulou K, Chalakatevaki K, Christidou A, Christodoulou DK, Bamias G, Michopoulos S, Zampeli E. Pregnancy outcomes in patients with inflammatory bowel disease: retrospective data from a Greek national registry. 31st UEGW, Copenhagen 2023

122. Zacharopoulou E, Viazis N, Psistakis A, Theodoropoulou A, Drygiannakis I, **Karmiris K**, Koutroubakis I, Kevrekidou P, Soufleris K, Katsaros M, Giouleme O, Fousekis F, Katsanos KH, Christodoulou DK, Gaki A, Bamias G, Papathanasiou E, Zampeli E, Michopoloulos S, Liatsos C, Kyriakos N, Veretanos C, Kapsoritakis AN, Argyriou K, Tribonias G, Mantzaris GJ, Tzouvala M. "Real-world" preliminary data on the efficacy and safety of 16-week induction therapy with tofacitinib in patients with ulcerative colitis. 31st UEGW, Copenhagen 2023

123. Chalakatevaki K, Kokkotis G, Chatzinikolaou M.L, Anagnostopoulou E, Argiriou K, Viazis N, Galanopoulos M, Gerasimatos G, Giouleme O, Zampeli E, Zacharopoulou E, Theodoropoulou A, Theocharis G, Kalogirou M, Karatzas P, **Karmiris K**, Kapsoritakis A, Koustenis K, Koutroubakis I, Kyriakos N, Lazou D, Liatsos C, Mantaka A, Mantzaris G, Michalopoulos G, Michopoulos S, Orfanidou A, Papathanasiou E, Polymeros D, Potamianos S, Sotiropoulos C, Soufleris K, Tzouvala M, Foteinogiannopoulou K, Chatzidakis A, Psistakis A, Bamias G. Real-word data on outcomes of treatment with ustekinumab in patients with ulcerative colitis. 19th Congress of ECCO, Stockholm 2024

***oral**

14^F PUBLICATIONS IN GREEK JOURNALS (IN ENGLISH)

1. **Karmiris K**, Koutroubakis IE. Role of infliximab in the treatment of fistulizing Crohn's disease. [Invited Review]. *Annals of Gastroenterology* 2005; 18:297-302

14^G POSTERS IN GREEK CONGRESSES

One hundred seven (107) oral presentations or posters in Hellenic Congresses (mainly annual Congress of Gastroenterology & IBD Congress)

14^H CHAPTER(S) IN BOOK(S)

1. **Karmiris K**, Koutroubakis IE, "Corticosteroids", chapter 6, p239-248 in "Inflammatory Bowel Diseases", Triantafillidis JK, Athens 2006 [Greek]

2. **Karmiris K**, Koutroubakis IE, "Novel therapies for Crohn's disease", e-book entitled: "Advances in the management of Inflammatory Bowel Disease", p134-145, 3/2013, www.futuremedicine.com.

14^I LECTURES IN INTERNATIONAL CONGRESSES

1. "Efficacy & safety of ADA in a single-center cohort of CD patients who failed to IFX treatment: the influence of trough serum levels", scientific session, 3rd Congress of ECCO, Lyon 2008
2. "Pouchitis" & "Fistulizing CD", ECCO Consensus implementation, Kaunas 2008
3. Pathogenesis Workshop "loss of response to anti-TNF monoclonal antibodies", 5th Congress of ECCO, Prague 2010
4. "Prevalence of extra-intestinal manifestations of IBD – Is there a role of gut-selective biologics?", 1st Hellenic-Israeli Gastro meeting, Heraklion Crete 2015
5. "Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumor necrosis factor alpha agents", 1st Hellenic- Israeli Gastro meeting, Heraklion Crete 2015
6. "Complications of immunosuppressants and biologic therapies in IBD", 56th ECCO Educational Workshop, Athens, 4/2018
7. "Emerging data with ustekinumab in Crohn's disease", session "Focus on 2020 IBD management", Webinar Janssen, 12/2020
8. "Extraintestinal manifestations", round tables session "7 themes/clinical cases discussion", 19th IBD Intensive Course for Trainees, 16th Congress of ECCO, virtual, 6/2021

9. "Treatment of anemia and improvement of quality of life", session "Complications in IBD", 5th IBDnet Summer School "Quality of care in IBD", Thun, 8/2021
10. "Imaging and new diagnostic steps in CD", 67th ECCO Educational Workshop, Taipei, 12/2021
11. "Surveillance and Chemoprevention in IBD", 67th ECCO Educational Workshop, Taipei, 12/2021
12. "5-ASA compounds", session "Introduction and case – based management on conventional IBD therapies", 20th IBD Intensive Course for Trainees, 17th Congress of ECCO, virtual, 2/2022
13. "Extraintestinal manifestations", "Round tables – 7 themes/clinical cases discussion", 20th IBD Intensive Course for Trainees, 17th Congress of ECCO, virtual, 2/2022
14. "5-ASA compounds", session "Introduction and case – based management on conventional IBD therapies", 21st IBD Intensive Course for Trainees, 18th Congress of ECCO, Copenhagen 2/2023
15. "Extraintestinal manifestations", "Round tables – 7 themes/clinical cases discussion", 21st IBD Intensive Course for Trainees, 18th Congress of ECCO, Copenhagen 2/2023
16. "5-ASA compounds", session "Introduction and case – based management on conventional IBD therapies", 21st IBD Intensive Course for Trainees, 19th Congress of ECCO, Stockholm 2/2024
17. "Extraintestinal manifestations", "Round tables – 7 themes/clinical cases discussion", 21st IBD Intensive Course for Trainees, 19th Congress of ECCO, Stockholm 2/2024

14^J LECTURES IN MAJOR GREEK CONGRESSES

1. "Safety of biologic therapies in IBD", scientific session, 4th Hellenic IBD Congress, Thessaloniki 2005
2. "Use of infliximab in the extraintestinal manifestations of IBD", satellite symposium, 5th Hellenic IBD Congress, Syros 2006
3. "Fistulizing CD", scientific session, 6th Hellenic IBD Congress, Heraklion 2007
4. "Mechanisms of carcinogenesis and early diagnosis in IBD", scientific session, 7th Hellenic IBD Congress, Corfu 2008
5. "Endoscopy in IBD: guiding the clinicians in taking therapeutic decisions", scientific session, 28th Hellenic Congress of Gastroenterology, Athens 2008
6. "Perianal CD: an interesting clinical challenge", satellite symposium, 8th Hellenic IBD Congress, Rhodes 2009
7. "Step up vs Top down therapeutic strategy in IBD", scientific session, 9th Hellenic IBD Congress, Limasol 2010
8. "The importance of early intervention in Crohn's disease", satellite symposium, 30th Hellenic Congress of Gastroenterology, Athens 2010
9. "Therapeutic targets with IMS and anti-TNF α biologic agents", postgraduate course, 10th Hellenic IBD Congress, Kalamata 2011
10. "A CD patient in clinical and laboratorial remission under azathioprine demonstrates a few aphthous ulcers in the large bowel: do we change treatment?", scientific session, 10th Hellenic IBD Congress, Kalamata 2011
11. "Describing the patient with Crohn's disease and prognostic factors for a disabling course", scientific session, 11th Hellenic IBD Congress, Porto Heli 2012
12. "Optimizing therapy with biologic agents in Crohn's disease patients", satellite symposium, 11th Hellenic IBD Congress, Porto Heli 2012
13. "Indications for the use of antiTNFs in Crohn's disease", scientific session, 32nd Hellenic Congress of Gastroenterology, Athens 2012
14. "Diagnostic and monitoring markers in IBD: Biochemical and stool markers", scientific session, 12th Hellenic IBD Congress, Volos 2013
15. "Best international publications in IBD during the last year", scientific session, 13th Hellenic IBD Congress, Delphi 2014

16. "Ulcerative colitis", clinical workshop, 34th Hellenic Congress of Gastroenterology, Athens 2014
17. "Best international publications in IBD during the last year", scientific session, 34th Hellenic Congress of Gastroenterology, Athens 2014
18. "Extra-intestinal manifestations (prevalence in Greek tertiary centers cohort)", scientific session, 14th Hellenic IBD Congress, Eretria 2015
19. "Calprotectin as a tool for diagnostic and therapeutic decisions / manipulations in IBD", scientific session, 35th Hellenic Congress of Gastroenterology, Kalamata 2015
20. "De-escalation/discontinuation of treatment in IBD: are we ready for this?", postgraduate course, 15th Hellenic IBD Congress, Ioannina 2016.
21. "The role of biosimilar infliximab in IBD: characteristics and efficacy data", satellite symposium, 15th Hellenic IBD Congress, Ioannina 2016.
22. "Therapy selection according to disease phase & behavior", scientific session, 36th Hellenic Congress of Gastroenterology, Athens 2016.
23. "Elderly patients with ulcerative colitis: IMS, antiTNFalpha agents or combination?" seminar "IBD in adolescents & elderly patients", 16th Hellenic IBD Congress, Nafplio 2017.

14^K PARTICIPATION IN INTERNATIONAL SCIENTIFIC MEETINGS

- [1] 1994: 1st Domestic Meeting of the European Hip Society, Ηράκλειο
- [2] 2003: International Symposium "Inflammatory Bowel Disease from the Bench to Bedside", Heraklion
- [3] 2003: 13th World Congress of the International Association of Surgeons & Gastroenterologists (IASG), Estoril, POR
- [4] 2004: Investigators Meeting for Protocol CHTF919 G2203 (Novartis), Paris, FRA
- [5] 2004: Falk Symposium No 140 "IBD: Translation from Basic Research to Clinical Practice", Dubrovnik, CRO
- [6] 2004: 12th United European Gastroenterology Week (UEGW) Prague, CZE
- [7] 2005: Falk Symposium No 147 "Colitis: Diagnosis and Therapeutic Strategies", Birmingham, GBR
- [8] 2005: Investigators Meeting for Protocol BUC-52/CDA (mc320), Berlin, GER
- [9] 2005: Falk Symposium No 149 "Highlights in Gastrointestinal Oncology", Berlin, GER
- [10] 2006: 1st Congress of the European Crohn's and Colitis Organization (ECCO), Amsterdam, NED
- [11] 2007: 2nd Congress of ECCO, Innsbruck, AUT
- [12] 2007: Falk Symposium No 159 "IBD 2007-achievements in research & clinical practice", Istanbul, TUR
- [13] 2007: 2nd Annual European Congress: Perspectives in Inflammatory Bowel Diseases, Brussels, BEL
- [14] 2007: 15th UEGW, Paris, FRA
- [15] 2008: 20th Belgian Week of Gastroenterology, Antwerp, BEL *
- [16] 2008: 3rd Congress of ECCO, Lyon, FRA*
- [17] 2008: 3rd ECCO Educational Workshop, Kaunas, LIT*
- [18] 2008: Digestive Disease Week (DDW), San Diego, USA*
- [19] 2008: 16th UEGW, Vienna, AUT*
- [20] 2009: 4th Congress of ECCO, Hamburg, GER
- [21] 2009: 17th UEGW, London, GBR
- [22] 2010: 5th Congress of ECCO, Prague, CZE*
- [23] 2010: Digestive Disease Week (DDW), New Orleans, USA
- [24] 2010: Annual meeting of the International Organisation for the study of IBD (IOIBD), Sissi Crete, GRE
- [25] 2011: 19th UEGW, Stockholm, SWE

- [26] 2012: 7th Congress of ECCO, Barcelona, ESP** (Poster chair)
- [27] 2012: 1st International IBD Expert Exchange, Leuven, BEL
- [28] 2013: 8th Congress of ECCO, Vienna, AUT** (Poster chair)
- [29] 2013: 2nd International IBD Expert Exchange, Calgary, CAN
- [30] 2013: 3rd International IBD Expert Exchange, Oxford, GBR
- [31] 2013: 21st UEGW, Berlin, GER
- [32] 2014: 9th Congress of ECCO, Copenhagen, DEN
- [33] 2015: 10th Congress of ECCO, Barcelona, ESP** (Poster chair)
- [34] 2015: Falk Symposium No 196 "Critical evaluation of current concepts and moving to new horizons in the management of IBD", Frankfurt GER
- [35] 2015: 1st Hellenic-Israeli Gastro meeting, Heraklion Crete, GRE*
- [36] 2015: 23rd UEGW, Barcelona, ESP
- [37] 2016: 11th Congress of ECCO, Amsterdam, NED** (Poster chair)
- [38] 2017: 12th Congress of ECCO, Barcelona, ESP
- [39] 2017: Falk Symposium No 206 "From the new and complex concepts to the real patient: science and clinic in IBD", Madrid ESP
- [40] 2018: 13th Congress of ECCO, Vienna, AUT
- [41] 2018: 56th ECCO Workshop, Athens*
- [42] 2018: 26th UEGW, Vienna 2018, AUT
- [43] 2019: 14th Congress of ECCO, Copenhagen, DEN
- [44] 2019: Falk Symposium No 215 "IBD: from diagnosis to therapy", St Petersburg RUS
- [45] 2020: 15th Congress of ECCO, Vienna, AUT
- [46] 2020: 28th UEGW (virtual)
- [47] 2020: Webinar: focus on 2020 IBD management, Janssen*
- [48] 2021: ESGE days 2021 (virtual)
- [49] 2021: 16th Congress of ECCO (virtual, speaker at the 20th IBD Intensive Course for Trainees)*
- [50] 2021: 29th UEGW (virtual)
- [51] 2021: AIBD, Orlando (virtual)
- [52] 2022: 17th Congress of ECCO (virtual, speaker at the 20th IBD Intensive Course for Trainees & chair in a session of the scientific program)*,**

* Speaker

** Chair